



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH



European Network of Centres for
Pharmacoepidemiology and
Pharmacovigilance

EMA/95098/2010 Rev.6

The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP)

Guide on Methodological Standards in Pharmacoepidemiology (Revision 6)

References

All hyperlinks in the document were last accessed on-line in June 2017.

References – Chapter 1

Altman D. *Practical Statistics for Medical Research*. Chapman & Hall, 1990.

Bégaud B. *Dictionary of Pharmacoepidemiology*. Wiley, 2000.

Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001.

<http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:2001L0083:20070126:en:PDF>

Elseviers M, Wettermark B, Almarsdóttir AB, et al. *Drug Utilization Research. Methods of Applications*. Wiley Blackwell, 2016.

Gail MH, Benichou J. *Encyclopedia of Epidemiologic Methods*. Wiley, 2000.

Guideline of good pharmacovigilance practices (GVP) Module VIII - Post-authorisation safety studies

http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp&mid=WC0b01ac058058f32c

Hartzema AG, Tilson HH, Chan KA. *Pharmacoepidemiology and Therapeutic Risk Management*. 1st Edition, Harvey Whitney Books Company, 2008.

IEA Good Epidemiology Practice (GEP)

<http://ieaweb.org/good-epidemiological-practice-gep/>

ISPE Guidelines for Good Pharmacoepidemiology Practices (GPP)

http://www.pharmacoepi.org/resources/guidelines_08027.cfm

30 Churchill Place • Canary Wharf • London E14 5EU • United Kingdom

Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555

Send a question via our website www.ema.europa.eu/contact

An agency of the European Union



MacMahon B, Trichopoulos D. *Epidemiology: Principles and Methods*. 2nd Edition, Lippincott Williams & Wilkins, 1996.

Porta M, Last JM, Greenland S. *A Dictionary of Epidemiology*. 5th Edition Oxford University Press, 2008.

Rothman K, Greenland S, Lash T. *Modern Epidemiology*. 3rd Edition, Lippincott Williams & Wilkins, 2008.

Strom B, Kimmel SE, Hennessy S. *Pharmacoepidemiology*. 5th Edition, Wiley, 2012.

References – Chapter 2

Brown P, Brunnhuber K, Chalkidou K, et al. How to formulate research recommendations. *BMJ : British Medical Journal*. 2006; 333(7572):804-806. doi: 10.1136/bmj.38987.492014.94.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1602035/>

European network of Health Technology Assessment (EUnetHTA). Position paper on how to formulate research recommendations
http://www.eunetha.eu/sites/default/files/sites/5026.fedimbo.belgium.be/files/news-attachments/eunetha_position_paper_on_research_recommendations_0.pdf

ISPE Guidelines for Good Pharmacoepidemiology Practices (GPP)
http://www.pharmacoepi.org/resources/guidelines_08027.cfm

References – Chapter 3

Agency for Healthcare Research and Quality (AHRQ)
<https://www.ahrq.gov/>

AHRQ. Developing a Protocol for Observational Comparative Effectiveness Research: A User's Guide
<http://www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=1166>

CIOMS International Ethical Guidelines for Health-related Research Involving Humans
<http://cioms.ch/shop/wp-content/uploads/2017/01/WEB-CIOMS-EthicalGuidelines.pdf>

Commission Implementing Regulation (EU) No 520/2012
<http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2012:159:0005:0025:EN:PDF>

Directive 2001/20/EC of the European Parliament and of the Council
<http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2001:121:0034:0044:en:PDF>

ENCePP Checklist for Study Protocols
http://www.encepp.eu/standards_and_guidances/checkListProtocols.shtml

European Medicines Agency. Guidance for the format and content of the final study report of non-interventional post-authorisation safety studies.
http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2013/01/WC500137939.pdf

European Medicines Agency. Guidance for the format and content of the protocol of non-interventional post-authorisation safety studies.
http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/10/WC500133174.pdf

FDA. Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Health Care Data Sets
<https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM243537.pdf>

Guideline on good pharmacovigilance practices (GVP) Module VI - Management and reporting of adverse reactions to medicinal products.
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp&mid=WC0b01ac058058f32c

Guideline of good pharmacovigilance practices (GVP) Module VIII - Post-authorisation safety studies
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp&mid=WC0b01ac058058f32c

ISPE Guidelines for Good Pharmacoepidemiology Practices (GPP)
http://www.pharmacoepi.org/resources/guidelines_08027.cfm

Volume 10 of the Rules Governing Medicinal Products in the European Union
<http://ec.europa.eu/health/documents/eudralex/vol-10/>

References – Chapter 4

Abenham L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G, Bégaud B, for the International Primary Pulmonary Hypertension Study Group. Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension. *N Engl J Med* 1996; 335:609-616 August 29, 1996.
<http://www.nejm.org/doi/full/10.1056/NEJM199608293350901>

ADVANCE project
<http://www.advance-vaccines.eu/?page=home>

Agency for Health Care Research and Quality (AHRQ). Registries for Evaluating Patient Outcomes: A User's Guide 3rd Edition.
<http://www.effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productID=1897>

Alvarez Y, Hidalgo A, Maignen F, Slattery J. Validation of statistical signal detection procedures in EudraVigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling. *Drug Saf.* 2010 Jun 1; 33(6): 475-87.
<https://www.ncbi.nlm.nih.gov/pubmed/20486730>

American Association for Public Opinion Research (AAPOR)
<https://www.aapor.org/>

American Association for Public Opinion Research (AAPOR). Standard Definitions. Final Dispositions of Case Codes and Outcome Rates for Surveys.
https://www.aapor.org/AAPOR_Main/media/publications/Standard-Definitions20169theditionfinal.pdf

ARITMO project
<https://www.aritmo-project.org/?q=content/synapse>

Banerjee AK, Ingate S. Web-based patient-reported outcomes in drug safety and risk management: challenges and opportunities? *Drug Saf.* 2012 Jun 1; 35(6): 437-46.
<https://www.ncbi.nlm.nih.gov/pubmed/22551007>

Berger ML, Mamdani M, Atkins D, Johnson ML. Good Research Practices for Comparative Effectiveness Research: Defining, Reporting and Interpreting Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—Part I.
<https://www.ispor.org/TaskForces/documents/RDPartI.pdf>

Bhattacharya M, Snyder S, Malin M, Truffa MM, Marinic S, Engelmann R, Raheja RR. Using Social Media Data in Routine Pharmacovigilance: A Pilot Study to Identify Safety Signals and Patient Perspectives. *Pharm Med* (2017) 31: 167-174.
<https://link.springer.com/article/10.1007/s40290-017-0186-6>

Bourke A, Bate A, Sauer BC, Brown JS, Hall GC. Evidence generation from healthcare databases: recommendations for managing change. *Pharmacoepidemiol Drug Saf* 2016; 25(7): 749-754.
<https://www.ncbi.nlm.nih.gov/pubmed/27183900>

Bouvy JC, Blake K, Slattery J, De Bruin ML, Arlett P, Kurz X. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005–2013. *Pharmacoepidemiol Drug Saf* 2017 Mar 26.
<https://www.ncbi.nlm.nih.gov/pubmed/28345151>

Canadian Network for Observational Drug Effect Studies (CNODES)
<https://www.cnodes.ca/>

Charlton R, De Vries C. Systematic overview of data sources for drug safety in pregnancy research
http://www.encepp.eu/structure/documents/Data_sources_for_medicines_in_pregnancy_research.pdf

CHMP Guideline on Conduct of Pharmacovigilance for Medicines Used by the Paediatric Population.
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003764.pdf

CIOMS Working Group VIII on Application of Signal Detection in Pharmacovigilance (CIOMS VIII). Practical Aspects of Signal Detection in Pharmacovigilance: Report of CIOMS Working Group VIII.
<http://www.cioms.ch/index.php/2012-06-10-08-47-53/working-groups/working-group-viii>

Cocos A, Fiks AG, Masino AJ. Deep learning for pharmacovigilance: recurrent neural network architectures for labelling adverse drug reactions in Twitter posts. *J Am Med Inform Assoc.* 2017 Feb 22.
<https://www.ncbi.nlm.nih.gov/pubmed/28339747>

Coloma PM, Becker B, Sturkenboom MCJM, van Mulligen EM, Kors JA. Evaluating Social Media Networks in Medicines Safety Surveillance: Two Case Studies. *Drug Saf.* 2015; 38(10): 921–930.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4579253/>

Coloma PM, Schuemie MJ, Trifirò G, Gini R, Herings R, Hippisley-Cox J, Mazzaglia G, Giaquinto C, Corrao G, Pedersen L, van der Lei J, Sturkenboom M; EU-ADR Consortium. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. *Pharmacoepidemiol Drug Saf* 2011;20(1):1-11.
<https://www.ncbi.nlm.nih.gov/pubmed/21182150>

Cox E, Martin BC, Van Staa T, Garbe E, Siebert U, Johnson ML. Good Research Practices for Comparative Effectiveness Research: Approaches to Mitigate Bias and Confounding in the Design of Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report—Part II.
<https://www.ispor.org/TaskForces/documents/RDPartII.pdf>

EMIF project
<http://www.emif.eu/>

Emilsson L, Lindahl B, Köster M, Lambe M, Ludvigsson JF. Review of 103 Swedish Healthcare Quality Registries. *J Intern Med*. 2015 Jan;277(1):94-136.
<https://www.ncbi.nlm.nih.gov/pubmed/25174800>

ENCePP Database of Research Resources
<http://www.encepp.eu/encepp/resourcesDatabase.jsp>

ENCePP Inventory of Data Sources
<http://www.encepp.eu/encepp/resourcesDatabase.jsp>

EU-ADR project
<https://www.euadr-project.org/>

EudraVigilance
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000679.jsp&mid=WC0b01ac05800250b5

EUnetHTA Joint Action 3
<http://www.eunetha.eu/activities/joint-action-3/jointaction31/eunetha-joint-action-3-2016-2020>

EUROCAT
<http://www.eurocat-network.eu/aboutus/whatiseurocat/whatiseurocat>

European Medicines Agency (EMA). Guideline for good clinical practice E6(R2)
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf

Fayers PM, Machin D. *Quality of Life: the assessment, analysis and interpretation of patient-related outcomes*. 2nd Edition, Wiley, 2007.

FDA. Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Health Care Data Sets
<https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM243537.pdf>

FDA. Guidance for Industry - Establishing Pregnancy Exposure Registries.
<https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071639.pdf>

FDA's Sentinel Initiative
<https://www.fda.gov/safety/fdassentinelinitiative/ucm2007250.htm>

Furu K, Kieler H, Haglund B, Engeland A, Selmer R, Stephansson O, Valdimarsdottir UA, Zoega H, Artama M, Gissler M, Malm H, Nørgaard M. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. *BMJ* 2015;350:h1798.
<http://www.bmj.com/content/bmj/350/bmj.h1798.full.pdf>

German Society for Epidemiology (DGEpi)
<http://dgepi.de/startseite.html>

German Society for Epidemiology (DGEpi). Good Practice in Secondary Data Analysis Version 2.
http://dgepi.de/fileadmin/pdf/leitlinien/gps-version2-final_ENG.pdf

Gini R, Schuemie M, Brown J, Ryan P, Vacchi E, Coppola M, Cazzola W, Coloma P, Berni R, Diallo G, Oliveira JL, Avillach P, Trifirò G, Rijnbeek P, Bellentani M, van Der Lei J, Klazinga N, Sturkenboom M. Data Extraction and Management in Networks of Observational Health Care Databases for Scientific Research: A Comparison of EU-ADR, OMOP, Mini-Sentinel and MATRICE Strategies. *EGEMS*. 2016 Feb.
<https://www.ncbi.nlm.nih.gov/pubmed/?term=Data+Extraction+and+Management+in+Networks+of+Observational+Health+Care+Databases+for+Scientific+Research%3A+A+Comparison+of+EU-ADR%2C+OMOP%2C+Mini-Sentinel+and+MATRICE+Strategies>

GRIP network

<http://www.grip-network.org/index.php/cms/en/home>

Groves RM, Fowler FJ, Couper MP et al. *Survey Methodology*. 2nd Edition, Wiley 2009.

Guideline on good pharmacovigilance practices (GVP) Module VI - Management and reporting of adverse reactions to medicinal products.

http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp&mid=WCOB01ac058058f32c

Guideline on good pharmacovigilance practices (GVP) Module VIII - Post-authorisation safety studies

http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp&mid=WCOB01ac058058f32c

Hall GC, Sauer B, Bourke A, Brown JS, Reynolds MW, Lo Casale R. Guidelines for Good Database Selection and use in Pharmacoepidemiology Research. *Pharmacoepidemiol Drug Saf* 2012; 21: 1-10.

<http://www.pharmacoepi.org/pub/1c2a306e-2354-d714-5127-9fd12e69fa66>

Hennessy S, Bilker WB, Weber A, Strom BL. Descriptive analyses of the integrity of a US Medicaid claims Database. *Pharmacoepidemiol Drug Saf* 2003; 12: 103–11.

<http://onlinelibrary.wiley.com/doi/10.1002/pds.765/pdf>

Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database (GPRD): a systematic review. *Br J Clin Pharmacol* 2010; 69: 4-14.

<http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.2009.03537.x/full>

HMO Research Network (HMORN)

https://epi.grants.cancer.gov/pharm/pharmacoepi_db/hmorn.html

International Society for Pharmacoconomics and Outcome Research (ISPOR)

<https://www.ispor.org/>

ISPE Guidelines for Good Pharmacoepidemiology Practices (GPP)

http://www.pharmacoepi.org/resources/guidelines_08027.cfm

Johnson ML, Crown W, Martin BC, Dormuth CR, Siebert U. Good Research Practices for Comparative Effectiveness Research: Analytic Methods to Improve Causal Inference from Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—Part III.

<https://www.ispor.org/TaskForces/documents/RDPartIII.pdf>

Jollis JG, Ancukiewicz M, DeLong ER, Pryor DB, Muhlbauer LH, Mark DB. Discordance of databases designed for claims payment versus clinical information systems: implications for outcomes research. *Ann Intern Med* 1993; 119: 844-50.

<http://annals.org/aim/article/706784/discordance-databases-designed-claims-payment-versus-clinical-information-systems-implications>

Kaufman DW, Rosenberg L, Mitchell AA. Signal generation and clarification: use of case-control data.

Pharmacoepidemiol Drug Saf. 2001 May; 10(3): 197-203.

<https://www.ncbi.nlm.nih.gov/pubmed/11501331>

Kieler H, Artama M, Engeland A, Ericsson Ö, Furu K, Gissler M, Beck Nielsen R, Nørgaard M, Stephansson O, Valdimarsdottir U, Zoega H, Haglund B. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic Countries. *BMJ* 2012; 344: d8012.

<http://www.bmj.com/content/344/bmj.d8012>

Klungel OH, Kurz X, de Groot MCH, Schlienger RG, Tcherny-Lessenot S, Grimaldi L, Ibáñez L, Groenwold RHH, Reynolds RF. Multi-centre, multi-database studies with common protocols: lessons learnt from the IMI PROTECT project. *Pharmacoepidemiol Drug Saf* 2016; 25(S1): 156-165.

<http://onlinelibrary.wiley.com/doi/10.1002/pds.3968/full>

Lepkowski JM, Tucker NC, Bricket JM. *Advances in telephone survey methodology*. Wiley 2007, Part V.

Norwegian Patient Registry

<https://helsedirektoratet.no/english/norwegian-patient-registry>

Observational Health Data Sciences and Informatics (OHDSI)

<https://www.ohdsi.org/>

Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. *J Am Med Inform Assoc*. 2012; 19(1): 54–60.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3240764/>

PARENT Joint Action
<http://parent-ror.eu/#/>

Pharmachild
<https://www.printo.it/projects/ongoing/15>

Powell GE, Seifert HA, Reblin T, Burstein PJ, Blowers J, Menius JA, Painter JL, Thomas M, Pierce CE, Rodriguez HW, Brownstein JS, Freifeld CC, Bell HG, Dasgupta N. Social Media Listening for Routine Post-Marketing Safety Surveillance. *Drug Saf*. 2016;39(5):443-54.
<https://www.ncbi.nlm.nih.gov/pubmed/26798054>

PROTECT project
<http://www.imi-protect.eu/about.shtml>

PROTECT project. Improving Consistency and Understanding of Discrepancies of Findings from Pharmacoepidemiological Studies: the IMI PROTECT Project. *Pharmacoepidemiol Drug Saf* 2016;25(S1): 1–165.
<http://onlinelibrary.wiley.com/doi/10.1002/pds.v25.S1/issuetoc>

Roberto G, Leal I, Sattar N, Loomis AK, Avillach P, Egger P, van Wijngaarden R, Ansell D, Reisberg S, Tammesoo ML, Alavere H, Pasqua A, Pedersen L, Cunningham J, Tramontan L, Mayer MA, Herings R, Coloma P, Lapi F, Sturkenboom M, van der Lei J, Schuemie MJ, Rijnbeek P, Gini R. Identifying Cases of Type 2 Diabetes in Heterogeneous Data Sources: Strategy from the EMIF Project. *PLoS ONE*. 2016;11(8):e0160648.
<https://www.ncbi.nlm.nih.gov/pubmed/?term=Identifying+Cases+of+Type+2+Diabetes+in+Heterogeneous+Data+Sources%3A+Strategy+from+the+EMIF>

Roujeau J-C, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, Auquier A, Bastuji-Garin S, Correia O, Locati F, Mockenhaupt M, Paoletti C, Shapiro S, Shear N, Schöpf E, Kaufman DW. Medication Use and the Risk of Stevens–Johnson Syndrome or Toxic Epidermal Necrolysis. *N Engl J Med* 1995; 333:1600-1608.
<http://www.nejm.org/doi/full/10.1056/NEJM199512143332404>

SAFEGUARD project
<http://www.safeguard-diabetes.org/>

Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. *Clin Epidemiol*. 2015 Nov 17;7:449-90.
<https://www.ncbi.nlm.nih.gov/pubmed/26604824>

Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. *J Clin Epidemiol*. 2005 Apr;58(4):323-37.
<https://www.ncbi.nlm.nih.gov/pubmed/15862718>

Shapiro, S. The design of a study of the drug etiology of agranulocytosis and aplastic anemia. *Eur J Clin Pharmacol* (1983) 24: 833.
<https://link.springer.com/article/10.1007%2FBF00607096>

Sloane R, Osanlou O, Lewis D, Bollegala D, Maskell S, Pirmohamed M. Social media and pharmacovigilance: A review of the opportunities and challenges. *Br J Clin Pharmacol*. 2015 Oct; 80(4): 910–920.
[https://www.ncbi.nlm.nih.gov/pubmed/?term=Social+media+and+pharmacovigilance%3A+A+review+of+the+opportunities+and+challenges+\(Br+J+Clin+Pharmacol.+2015+Oct%3B+80\(4\)%3A+910%E2%80%93920\)](https://www.ncbi.nlm.nih.gov/pubmed/?term=Social+media+and+pharmacovigilance%3A+A+review+of+the+opportunities+and+challenges+(Br+J+Clin+Pharmacol.+2015+Oct%3B+80(4)%3A+910%E2%80%93920))

SOS project
<https://www.sos-nsaids-project.org/>

Streiner DL, Norman GR. *Health Measurement Scales: a practical guide to their development and use*. 4th Edition, Oxford University Press, 2008.

Strom B, Kimmel SE, Hennessy S. *Pharmacoepidemiology*. 5th Edition, Wiley, 2012.

Swedish National Patient Register
<http://www.socialstyrelsen.se/register/halsodataregister/patientregistret/inenglish>

The European Union electronic Register of Post-Authorisation Studies (EU PAS Register)
http://www.encepp.eu/encepp_studies/indexRegister.shtml

The U.S. Food and Drug Administration's Mini-Sentinel Program. *Pharmacoepidemiol Drug Saf* 2012;21(S1): 1–303.
<http://onlinelibrary.wiley.com/doi/10.1002/pds.v21.S1/issuetoc>

Tregunno PM, Fink DB, Fernandez-Fernandez C, Lázaro-Bengoia E, Norén GN. Performance of probabilistic method to detect duplicate individual case safety reports. *Drug Saf* 2014;37(4):249-58.
<https://www.ncbi.nlm.nih.gov/pubmed/24627310>

UK Renal Registry
<https://www.renalreg.org/about-us/>

Vander Stichele RH, Elseviers MM, Ferech M, Blot S, Goossens H. European Surveillance of Antimicrobial Consumption (ESAC): Data Collection Performance and Methodological Approach. *Br J Clin Pharmacol* 2004;58: 419-28.
<http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.2004.02164.x/abstract>

Verstraeten T, DeStefano F, Chen RT, Miller E. Vaccine safety surveillance using large linked databases: opportunities, hazards and proposed guidelines. *Expert Rev Vaccines* 2003; 2(1):21-9.
<https://www.ncbi.nlm.nih.gov/pubmed/12901594>

WEB-RADR

<https://web-radr.eu/about-us/>

WHO Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical Classification System.
https://www.whocc.no/atc/structure_and_principles/

WHO Collaborating Centre for Drug Statistics Methodology. Defined Daily Doses.
https://www.whocc.no/ddd/definition_and_general_considera/

WHO. The Global Individual Case Safety Reports Database System (VigiBase).
<https://www.who-umc.org/vigibase/vigibase/>

Wisniewski AFZ, Juhlin K, Vestergaard Laursen M, Macia MM, Manlik K, Pinkston VK, Seabroke S, Slattery J (PROTECT project). Characterization of databases (DB) used for signal detection (SD).
<http://www.imi-protect.eu/documents/WisniewskietalCharacterisationofdatabasesusedorsignaldetectionposterfinalCPE2012.pdf>

Xu Y, Zhou X, Suehs BT, Hartzema AG, Kahn MG, Moride Y, Sauer BC, Liu Q, Moll K, Pasquale MK, Nair VP, Bate A. A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance. *Drug Saf.* 2015;38(8):749-65.
<https://www.ncbi.nlm.nih.gov/pubmed/26055920>

References – Chapter 5

Ali MS, Groenwold RH, Pestman WR, Belitser SV, Roes KC, Hoes AW, de Boer A, Klungel OH. Propensity score balance measures in pharmacoepidemiology: a simulation study. *Pharmacoepidemiol Drug Saf* 2014; Epub 2014 Jan 29.
<https://www.ncbi.nlm.nih.gov/pubmed/24478163>

Ali MS, Groenwold RH, Belitser SV, Pestman WR, Hoes AW, Roes KC, Boer Ad, Klungel OH. Reporting of covariate selection and balance assessment in propensity score analysis is suboptimal: a systematic review. *J Clin Epidemiol.* 2015;68(2):112-21.
<https://www.ncbi.nlm.nih.gov/pubmed/25433444>

Ali MS, Uddin MJ, Groenwold RH, Pestman WR, Belitser SV, Hoes AW, de Boer A, Roes KC, Klungel OH. Quantitative falsification of instrumental variables assumption using balance measures. *Epidemiology.* 2014;25(5):770-2.
<https://www.ncbi.nlm.nih.gov/pubmed/25076152>

Altman DG, Bland JM. Interaction revisited: the difference between two estimates. *BMJ* 2003;326:219.
<https://www.ncbi.nlm.nih.gov/pubmed/12543843>

Arbogast PG, Ray WA. Use of disease risk scores in pharmacoepidemiologic studies. *Stat Methods Med Res* 2009;18:67-80.
<http://journals.sagepub.com/doi/abs/10.1177/0962280208092347>

Baiocchi M, Cheng J, Small DS. Instrumental variable methods for causal inference. *Stat Med.* 2014;33(13):2297-340.
<https://www.ncbi.nlm.nih.gov/pubmed/24599889>

Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting. *Pharmacoepidemiol Drug Saf* 2009;18:427-36.
<http://onlinelibrary.wiley.com/doi/10.1002/pds.1742/abstract>

Belitser SV, Martens EP, Pestman WR, Groenwold RH, de Boer A, Klungel OH. Measuring balance and model selection in propensity score methods. *Pharmacoepidemiol Drug Saf* 2011;20:1115-29.
<https://www.ncbi.nlm.nih.gov/pubmed/21805529>

Berlin C, Blanch C, Lewis DJ, Maladorno DD, Michel C, Petrin M, Sarp S, Close P. Are all quantitative postmarketing signal detection methods equal? Performance characteristics of logistic regression and Multi-item Gamma Poisson Shrinker (Pharmacoepidemiol. *Drug Saf.* 2012; 21, 622–630.
<https://www.ncbi.nlm.nih.gov/pubmed/21994119>

Brighton Collaboration. Case definitions.

<https://brightoncollaboration.org/public/what-we-do/setting-standards/case-definitions.html>

- Brookhart MA, Wang P, Solomon DH, Schneeweiss S. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. *Epidemiology* 2006; 17(3): 268-75.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2715942/>
- Brookhart MA, Rassen JA, Schneeweiss S. Instrumental variable methods in comparative safety and effectiveness research. *Pharmacoepidemiol Drug Saf* 2010; 19: 537–54.
<http://onlinelibrary.wiley.com/doi/10.1002/pds.1908/abstract>
- Brunelli SM, Gagne JJ, Huybrechts KF, Wang SV, Patrick AR, Rothman KJ, Seeger JD. Estimation using all available covariates information versus a fixed look-back window for dichotomous covariates. *Pharmacoepidemiol Drug Saf*. 2013; 22(5): 542-50.
<https://www.ncbi.nlm.nih.gov/pubmed/23526818>
- Candore G, Juhlin K, Manlik K, Thakrar B, Quarcoo N, Seabroke S, Wisniewski A, Slattery J. Comparison of Statistical Detection Methods within and across Spontaneous Reporting Databases. *Drug Saf* 2015; 38(6); 577-87.
<https://link.springer.com/article/10.1007/s40264-015-0289-5>
- Carnahan RM, Moores KG. Mini-Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative and claims data: methods and lessons learned. *Pharmacoepidemiol Drug Saf*. 2012 Jan; 21 Suppl 1: 82-9.
<https://www.ncbi.nlm.nih.gov/pubmed/22262596>
- Caster O, Norén GN, Madigan D, Bate A. Large scale regression-based pattern discovery: the example of screening the WHO global drug safety database. *Stat. Anal. Data Min* 2010; 3, 197–208.
<http://onlinelibrary.wiley.com/doi/10.1002/sam.10078/abstract>
- Caster O, Norén GN, Madigan D, Bate A. Logistic regression in signal detection: Another Piece added to the Puzzle. *Clin Pharmacol Ther* 2013; 94 (3): 312.
<https://www.ncbi.nlm.nih.gov/pubmed/23695184>
- Caster O, Juhlin K, Watson S, Norén GN. Improved statistical signal detection in pharmacovigilance by combining multiple strength-of-evidence aspects in *vigiRank*. *Drug Saf* 2014; 37(8): 617–28.
<https://www.ncbi.nlm.nih.gov/pubmed/25052742>
- Chou R, Helfand M. Challenges in systematic reviews that assess treatment harms. *Ann Intern Med* 2005; 142: 1090-9.
<http://annals.org/aim/article/718519/challenges-systematic-reviews-assess-treatment-harms>
- CIOMS Working Group VIII Practical Aspects of Signal Detection in Pharmacovigilance.
<http://www.cioms.ch/index.php/2012-06-10-08-47-53/working-groups/working-group-viii>
- CIOMS Working Group X. Guideline on Evidence Synthesis and Meta-Analysis for Drug Safety (Geneva 2016).
<http://www.cioms.ch/index.php/12-newsflash/312-cioms-working-group-x-on-considerations-for-applying-good-meta-analysis-practices-to-clinical-safety-data-within-the-biopharmaceutical-regulatory-process>
- ClinicalCodes.org
<https://clinicalcodes.rss.mhs.man.ac.uk/>
- Cole SR, Hernán MA, Robins JM, Anastos K, Chmiel J, Detels R, Ervin C, Feldman J, Greenblatt R, Kingsley L, Lai S, Young M, Cohen M, Muñoz A. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. *Am J Epidemiol* 2003; 158: 687-94.
<https://www.ncbi.nlm.nih.gov/pubmed/14507605>
- Collier S, Harvey C, Brewster J, Bakerly ND, Elkhenini HF, Stanciu R, Williams C, Brereton J, New JP, McCrae J, McCorkindale S, Leather D. Monitoring safety in a phase III real-world effectiveness trial: use of novel methodology in the Salford Lung Study. *Pharmacoepidemiol Drug Saf*. 2017; 26(3): 344-352.
<https://www.ncbi.nlm.nih.gov/pubmed/27804174>
- Daniel RM, Cousens SN, De Stavola BL, Kenward MG, Sterne JA. Methods for dealing with time-dependent confounding. *Stat Med*. 2013; 32(9): 1584-618.
<https://www.ncbi.nlm.nih.gov/pubmed/23208861>
- Davé S, Petersen I. Creating medical and drug code lists to identify cases in primary care databases. *Pharmacoepidemiol Drug Saf* 2009; 18(8): 704-7.
<https://www.ncbi.nlm.nih.gov/pubmed/19455565>
- Division of Pharmacoepidemiology and Pharmacoconomics, Brigham and Women's Hospital Department of Medicine. Pharmacoepidemiology Toolbox.
<http://www.drugapi.org/dope-downloads/>
- Elseviers M, Wettermark B, Almarsdottir AB et al. *Drug Utilization Research. Methods and Applications*. Wiley Blackwell, 2016.

ENCePP Database of Research Resources

<http://www.encepp.eu/encepp/resourcesDatabase.jsp>

EudraVigilance

http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000679.jsp&mid=WC0b01ac05800250b5

European Medicines Agency. Guideline on the use of statistical signal detection methods in the Eudravigilance data analysis system.

http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/11/WC500011434.pdf

Farrington CP, Whitaker HJ, Hoxby MN. Cases series analysis for censored, perturbed, or curtailed post-event exposures. *Biostatistics* 2009;10(1):3-16.

<https://www.ncbi.nlm.nih.gov/pubmed/18499654>

Farrington CP. Control without separate controls: evaluation of vaccine safety using case-only methods. *Vaccine* 2004;22(15-16):2064-70.

<https://www.ncbi.nlm.nih.gov/pubmed/15121324>

FDA. Guidance for Industry-Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment.

<https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071696.pdf>

FDA's Sentinel Initiative

<https://www.fda.gov/Safety/FDAsSentinelInitiative/ucm149341.htm>

Fewell Z, Smith GD, Sterne JAC. The impact of residual and unmeasured confounding in epidemiologic studies: a simulation study. *Am J Epidemiol* 2007;166:646–55.

<https://academic.oup.com/aje/article/166/6/646/89040/The-Impact-of-Residual-and-Unmeasured-Confounding?ijkey=cd9eebd0b1e1cb0cb5c027d7c17069f5f7c9e526>

Franklin JM, Rassen JA, Ackermann D, Bartels DB, Schneeweiss S. Metrics for covariate balance in cohort studies of causal effects. *Stat Med* 2013;33:1685-99.

<https://www.ncbi.nlm.nih.gov/pubmed/24323618>

Fröbert O, Lagerqvist B, Olivecrona GK, Omerovic E, Gudnason T, Maeng M, Aasa M, Angerås O, Calais F, Danielewicz M, Erlinge D, Hellsten L, Jensen U, Johansson AC, Käregren A, Nilsson J, Robertson L, Sandhall L, Sjögren I, Östlund O, Harnek J, James SK. Thrombus aspiration during ST-segment elevation myocardial infarction. *N. Engl J Med*. 2013;369(17):1587-97.

<http://www.nejm.org/doi/full/10.1056/NEJMoa1308789>

Garabedian LF, Chu P, Toh S, Zaslavsky AM, Soumerai SB. Potential bias of instrumental variable analyses for observational comparative effectiveness research. *Ann Intern Med*. 2014;161(2):131-8.

<https://www.ncbi.nlm.nih.gov/pubmed/25023252>

Gerhard T. Bias: Considerations for research practice. *Am J Health Syst Pharm* 2008;65:2159-68.

<https://www.ncbi.nlm.nih.gov/pubmed/18997149>

GetReal project. Glossary of Definitions of Common Terms

https://www.imi-getreal.eu/Portals/1/Documents/01%20Deliverables/D1.3%20-%20Revised%20GetReal%20glossary%20-%20FINAL%20updated%20version_25Oct16_webversion.pdf

Glynn RJ, Gagne JJ, Schneeweiss S. Role of disease risk scores in comparative effectiveness research with emerging therapies. *Pharmacoepidemiol Drug Saf*. 2012 May;21 Suppl 2:138–47.

<https://www.ncbi.nlm.nih.gov/pubmed/22552989>

Greenland S. Confounding and exposure trends in case-crossover and case-time-control designs. *Epidemiology*. 1996;7:231-9.

<https://www.ncbi.nlm.nih.gov/pubmed/8728434>

Greenland S. An introduction to instrumental variables for epidemiologists. *Int J Epidemiol* 2000;29:722-9.

<https://academic.oup.com/ije/article/29/4/722/765560/An-introduction-to-instrumental-variables-for?eaf>

Grobbée DE, Hoes AW. Confounding and indication for treatment in evaluation of drug treatment for hypertension. *BMJ* 1997;315:1151-4.

<http://www.bmj.com/content/315/7116/1151>

Groenwold RH, de Vries F, de Boer A, Pestman WR, Rutten FH, Hoes AW, Klungel OH. Balance measures for propensity score methods: a clinical example on beta-agonist use and the risk of myocardial infarction. *Pharmacoepidemiol Drug Saf* 2011;20(11):1130-7.

<https://www.ncbi.nlm.nih.gov/pubmed/21953948>

Guideline on good pharmacovigilance practices (GVP) Module IX - Signal Management

http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp&mid=WCOB01ac058058f32c

Gulmez SE, Larrey D, Pageaux GP, Lignot S, Lassalle R, Jové J, Gatta A, McCormick PA, Metselaar HJ, Monteiro E, Thorburn D, Bernal W, Zouboulis-Vafiadis I, de Vries C, Perez-Gutthann S, Sturkenboom M, Bénichou J, Montastruc JL, Horsmans Y, Salvo F, Hamoud F, Micon S, Droz-Perroteau C, Blin P, Moore N. Transplantation for Acute Liver Failure in Patients Exposed to NSAIDs or Paracetamol (Acetaminophen). *Drug Saf* 2013;36:135–44.

<https://www.ncbi.nlm.nih.gov/pubmed/23325533>

Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. *Epidemiology* 1996;7(5):478-84.

<https://www.ncbi.nlm.nih.gov/pubmed/8862977>

Hallas J, Pottegård A, Wang S, Schneeweiss S, Gagne JJ. Persistent User Bias in Case-Crossover Studies in Pharmacoepidemiology. *Am J Epidemiol*. 2016 Oct 25., Epub ahead of print.

<https://www.ncbi.nlm.nih.gov/pubmed/27780801>

Harpaz R, DuMouchel W, LePendou P, Bauer-Mehren A, Ryan P, ShahNH. Performance of Pharmacovigilance Signal Detection Algorithms for the FDA Adverse Event Reporting System. *Clin Pharmacol Ther* 2013;93(6):539-46.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3857139/>

Hauben M, Madigan D, Gerrits CM, Walsh L, Van Puijenbroek EP. The role of data mining in pharmacovigilance. *Expert Opin Drug Saf* 2005;4(5):929-48.

<https://www.ncbi.nlm.nih.gov/pubmed/16111454>

Haut ER, Pronovost PJ. Surveillance Bias in Outcomes Reporting. *JAMA*, 2011;305(23):2462-3.

<http://jamanetwork.com/journals/jama/fullarticle/900883>

Henry D, Lim LLY, Garcia Rodriguez LA, Gutthann SP, Carson JL, Griffin M, Savage R, Logan R, Moride Y, Hawkey C, Hill S, Fries JT. Variability in risk of gastrointestinal complications with individual NSAIDs: results of a collaborative meta-analysis. *BMJ* 1996;312:1563-6.

<http://www.bmj.com/content/312/7046/1563>

Hernán MA, Brumback B, Robins JM. Marginal Structural Models to Estimate the Causal Effect of Zidovudine on the Survival of HIV-Positive Men. *Epidemiology* 2000;11:561–70.

<https://www.ncbi.nlm.nih.gov/pubmed/10955409>

Horwitz RI, Feinstein AR. Alternative analytic methods for case-control studies of estrogens and endometrial cancer. *N Engl J Med* 1978;299(20):1089-94.

<http://www.nejm.org/doi/full/10.1056/NEJM197811162992001>

Joffe MM. Confounding by indication: the case of the calcium channel blockers. *Pharmacoepidemiol Drug Saf* 2000;9:37-41.

[http://onlinelibrary.wiley.com/doi/10.1002/\(SICI\)1099-1557\(200001/02\)9%3A1%3C37%3A%3AAID-PDS471%3E3.0.CO;2-U/abstract](http://onlinelibrary.wiley.com/doi/10.1002/(SICI)1099-1557(200001/02)9%3A1%3C37%3A%3AAID-PDS471%3E3.0.CO;2-U/abstract)

Joffe MM, Rosenbaum PR. Invited Commentary: Propensity Scores. *Am J Epidemiol* 1999;150:327–33.

<https://www.ncbi.nlm.nih.gov/pubmed/10453808>

Juhlin K, Ye X, Star K, Norén GN. Outlier removal to uncover patterns in adverse drug reaction surveillance - a simple unmasking strategy. *Pharmacoepidemiol Drug Saf* 2013;22(10):1119-29.

<https://www.ncbi.nlm.nih.gov/pubmed/23832706>

Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research Database: a systematic review. *Br J Gen Pract* 2010;60:e128-36.

<https://www.ncbi.nlm.nih.gov/pubmed/20202356>

Kiri VA, MacKenzie G. Re. 'Immortal time bias on pharmacoepidemiology'. *Am J Epidemiol* 2009; 170: 667-8.

<https://academic.oup.com/aje/article/170/5/667/103807/RE-IMMORTAL-TIME-BIAS-IN-PHARMACOEPIDEMIOLOGY>

Klungle OH, Martens EP, Psaty BM, Grobbee DE, Sullivan SD, Stricker BH, Leufkens HG, de Boer A. Methods to assess intended effects of drug treatment in observational studies are reviewed. *J Clin Epidemiol* 2004;57:1223-31.

<https://www.ncbi.nlm.nih.gov/pubmed/15617947>

Knol MJ, VanderWeele TJ. Recommendations for presenting analyses of effect modification and interaction. *Int J Epidemiol* 2012;41:514-20.

<https://www.ncbi.nlm.nih.gov/pubmed/22253321>

Knol MJ, VanderWeele TJ, Groenwold RH, Klungel OH, Rovers MM, Grobbee DE. Estimating measures of interaction on an additive scale for preventive exposures. *Eur J Epidemiol* 2011;26(6):433-8.

<https://www.ncbi.nlm.nih.gov/pubmed/21344323>

- Lauer MS, D'Agostino RB Sr. The randomized registry trial--the next disruptive technology in clinical research? *N Engl J Med*. 2013 Oct 24;369(17):1579-81. doi: 10.1056/NEJMp1310102. Epub 2013 Aug 31.
<https://www.ncbi.nlm.nih.gov/pubmed/23991657>
- Lee WJ, Lee TA, Pickard AS, Shoaibi A, Schumock GT. Using linked electronic data to validate algorithms for health outcomes in administrative databases. *J Comp Eff Res*. 2015 Aug;4(4):359-66.
<https://www.ncbi.nlm.nih.gov/pubmed/26274797>
- Lesko SM, Mitchell AA. Assessment of the safety of paediatric ibuprofen: a practitioner based randomised clinical trial. *JAMA* 1995;279:929-33.
<https://www.ncbi.nlm.nih.gov/pubmed/7884951>
- Lévesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. *BMJ* 2010; 340:b5087.
<http://www.bmj.com/content/340/bmj.b5087>
- Lewis MA. The Transnational Study on Oral Contraceptives and the Health of Young Women. Methods, results, new analyses and the healthy user effect. *Hum Reprod Update*. 1999 Nov-Dec;5(6).
<https://www.ncbi.nlm.nih.gov/pubmed/10652980>
- Loudon K, Treweek S, Sullivan F, Cheesbrough GF, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. *BMJ* 2015; 350: h2147.
<http://www.bmj.com/content/350/bmj.h2147>
- Maclure M. The Case-Crossover Design: A Method for Studying Transient Effects on the Risk of Acute Events. *Am J Epidemiol* 1991;133:144-53.
<https://academic.oup.com/aje/article-abstract/133/2/144/118507/The-Case-Crossover-Design-A-Method-for-Studying>
- Maclure M, Fireman B, Nelson JC, Hua W, Shoaibi A, Paredes A, Madigan D. When should case-only designs be used for safety monitoring of medicinal products? *Pharmacoepidemiol Drug Saf* 2012;21(Suppl. 1):50-61.
<https://www.ncbi.nlm.nih.gov/pubmed/22262593>
- Maignen F, Hauben M, Hung E, Holle LV, Dogne JM. A conceptual approach to the masking effect of measures of disproportionality. *Pharmacoepidemiol Drug Saf* 2014;23(2):208-17.
<https://www.ncbi.nlm.nih.gov/pubmed/24243699>
- Maignen F, Hauben M, Hung E, Van Holle L, Dogne JM. Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases. *Pharmacoepidemiol Drug Saf* 2014;23(2):195-207.
<https://www.ncbi.nlm.nih.gov/pubmed/24243665>
- Martens EP, Pestman WR, de Boer A, Belitser SV, Klungel OH. Instrumental variables: application and limitations. *Epidemiology* 2006;17:260-7.
<https://www.ncbi.nlm.nih.gov/pubmed/16617274>
- McMahon AD. Approaches to combat with confounding by indication in observational studies of intended drug effects. *Pharmacoepidemiol Drug Saf* 2003;12:551-8.
<http://onlinelibrary.wiley.com/doi/10.1002/pds.883/pdf>
- Medical Dictionary for Regulatory Activities (MedDRA)
<https://www.meddra.org/>
- Miettinen OS. Stratification by a multivariate confounder score. *Am J Epidemiol* 1976;104:609-20.
<https://academic.oup.com/aje/article-abstract/104/6/609/139285/STRATIFICATION-BY-A-MULTIVARIATE-CONFOUNDER-SCORE>
- Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG; Consolidated Standards of Reporting Trials Group. CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. *J Clin Epidemiol* 2010;63(8):e1-37.
<https://www.ncbi.nlm.nih.gov/pubmed/20346624>
- Moodie EE, Stephens DA. Using directed acyclic graphs to detect limitations of traditional regression in longitudinal studies. *Int J Public Health* 2010;55:701-3.
<https://www.ncbi.nlm.nih.gov/pubmed/20838848>
- Moore N, Gulmez SE, Larrey D, Pageaux GP, Lignot S, Lassalle R, Jové J, Pariente A, Blin P, Bénichou J, Bégaud B. Choice of the denominator in case population studies: event rates for registration for liver transplantation after exposure to NSAIDs in the SALT study in France. *Pharmacoepidemiol Drug Saf* 2013;22(2):160-7.
<https://www.ncbi.nlm.nih.gov/pubmed/23166053>
- Moride Y, Abenheim L. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. *J Clin Epidemiol* 1994;47(7):731-7.
<https://www.ncbi.nlm.nih.gov/pubmed/7722586>

Nicholas JM, Grieve AP, Gulliford MC. Within-person study designs had lower precision and greater susceptibility to bias because of trends in exposure than cohort and nested case-control designs. *J Clin Epidemiol* 2012; 65(4):384-93.
<https://www.ncbi.nlm.nih.gov/pubmed/22197519>

Norén GN, Edwards IR. Modern methods of pharmacovigilance: detecting adverse effects of drugs. *Clin Med* 2009; 9(5):486-9.
<http://www.clinmed.rcpjournals.org/content/9/5/486.full>

Observational Medical Outcomes Partnership (OMOP)
<http://omop.org/>

Observational Health Data Sciences and Informatics (OHDSI)
<https://www.ohdsi.org/>

Pottegård A, Christensen R, Houji A, Christiansen CB, Paulsen MS, Thomsen JL, Hallas J. Primary non-adherence in general practice: a Danish register study. *Eur J Clin Pharmacol* 2014; 70(6):757-63.
<https://www.ncbi.nlm.nih.gov/pubmed/24756147>

PROTECT project.
<http://www.imi-protect.eu/wp3.shtml>

PROTECT project. Inventory of Drug Consumption Databases in Europe.
<http://www.imi-protect.eu/drugConsumption.shtml>

PROTECT project. Database of adverse drug reactions (EU SPC ADR database).
<http://www.imi-protect.eu/methodsRep.shtml>

Rassen JA, Schneeweiss S. Using high-dimensional propensity score to automate confounding control in a distributed medical product safety surveillance system. *Pharmacoepidemiol Drug Saf* 2012; 21(S1):41-9.
<http://onlinelibrary.wiley.com/doi/10.1002/pds.2328/abstract>

Rassen JA, Shelat AA, Myers J, Glynn RJ, Rothman KJ, Schneeweiss S. One-to-many propensity score matching in cohort studies. *Pharmacoepidemiol Drug Saf*. 2012; 21(S2):69-80.
<https://www.ncbi.nlm.nih.gov/pubmed/22552982>

Rassen JA, Shelat AA, Franklin JM, Glynn RJ, Solomon DH, Schneeweiss S. Matching by propensity score in cohort studies with three treatment groups. *Epidemiology* 2013; 24(3):401-9.
<https://www.ncbi.nlm.nih.gov/pubmed/23532053>

Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. *Am J Epidemiol* 2003; 158 (9):915-20.
<https://academic.oup.com/aje/article/158/9/915/102549/Evaluating-Medication-Effects-Outside-of-Clinical>

Robins JM, Hernán MA, Brumback B. Marginal Structural Models and Causal Inference in Epidemiology. *Epidemiology* 2000; 11:550-60.
<https://www.ncbi.nlm.nih.gov/pubmed/10955408>

Rothman K, Greenland S, Lash T. *Modern Epidemiology*. 3rd Edition, Lippincott Williams & Wilkins, 2008.

Salvo F, Leborgne F, Thiessard F, Moore N, Bégaud B, Pariente A. A potential event-competition bias in safety signal detection: results from a spontaneous reporting research database in France. *Drug Saf* 2013; 36(7):565-72.
<https://www.ncbi.nlm.nih.gov/pubmed/23673817>

Sanni Ali M, Groenwold RH, Pestman WR, Belitser SV, Hoes AW, de Boer A, Klungel OH. Time-dependent propensity score and collider-stratification bias: an example of beta(2)-agonist use and the risk of coronary heart disease. *Eur J Epidemiol* 2013; 28(4):291-9.
<https://www.ncbi.nlm.nih.gov/pubmed/23354982>

Schmidt AF, Klungel OH, Groenwold RH; GetReal Consortium. Adjusting for Confounding in Early Postlaunch Settings: Going Beyond Logistic Regression Models. *Epidemiology*. 2016; 27:133-42.
<https://www.ncbi.nlm.nih.gov/pubmed/26436519>

Schmidt AF, Groenwold RH, Knol MJ, Hoes AW, Nielen M, Roes KC, de Boer A, Klungel OH. Exploring interaction effects in small samples increases rates of false-positive and false-negative findings: results from a systematic review and simulation study. *J Clin Epidemiol* 2014; 67(7):821-9.
<https://www.ncbi.nlm.nih.gov/pubmed/24768005>

Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. *Pharmacoepidemiol Drug Saf* 2006; 15(5):291-303.
<http://onlinelibrary.wiley.com/doi/10.1002/pds.1200/abstract>

Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. *J Clin Epidemiol* 2005;58(4): 323-37.
<https://www.ncbi.nlm.nih.gov/pubmed/15862718>

Schneeweiss S, Stürmer T, Maclure M. Case-crossover and Case-Time-Control Designs as Alternatives in Pharmacoepidemiologic Research. *Pharmacoepidemiol Drug Saf* 1997; Suppl 3. S51-S59.
<https://www.ncbi.nlm.nih.gov/pubmed/15073755>

Seabroke S, Candore G, Juhlin K, Quarcio N, Wisniewski A, Arani R, Painter J, Tregunno P, Norén GN, Slattery J. Performance of Stratified and Subgrouped Disproportionality Analyses in Spontaneous Databases. *Drug Saf* 2016; 39(4): 355-364.
<https://www.ncbi.nlm.nih.gov/pubmed/26748507>

Self Controlled Case Series Method
<http://statistics.open.ac.uk/sccs>

Stephenson WP, Hauben M. Data mining for signals in spontaneous reporting databases: proceed with caution. *Pharmacoepidemiol Drug Saf* 2007; 16: 359–65.
<http://onlinelibrary.wiley.com/doi/10.1002/pds.1323/abstract>

Strom BL, Kimmel SE, Hennessy S. *Pharmacoepidemiology*. 5th Edition, Wiley, 2012.

Strom BL, Eng SM, Faich G, Reynolds RF, D'Agostino RB, Ruskin J, Kane JM. Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Zodiac Observational Study of Cardiac Outcomes (ZODIAC). *Am J Psychiatry* 2011; 168(2): 193-201.
<https://www.ncbi.nlm.nih.gov/pubmed/21041245>

Stürmer T, Schneeweiss S, Rothman KJ, Avorn J, Glynn RJ. Performance of propensity score calibration – a simulation study. *Am J Epidemiol* 2007; 165(10): 1110-8.
<https://www.ncbi.nlm.nih.gov/pubmed/17395595>

Stürmer T, Rothman KJ, Avorn J, Glynn RJ. Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study. *Am J Epidemiol*. 2010; 172(7): 843–54.
<https://www.ncbi.nlm.nih.gov/pubmed/20716704>

Suchard MA, Zorych I, Simpson SE, Schuemie MJ, Ryan PB, Madigan D. Empirical performance of the self-controlled case series design: lessons for developing a risk identification and analysis system. *Drug Saf* 2013; 36(Suppl. 1): S83-S93.
<https://www.ncbi.nlm.nih.gov/pubmed/24166226>

Suissa S. Immortal time bias in observational studies of drug effects. *Pharmacoepidemiol Drug Saf* 2007; 16: 241-9.
<http://onlinelibrary.wiley.com/doi/10.1002/pds.1357/abstract>

Suissa S. Immortal time bias in Pharmacoepidemiology. *Am J Epidemiol* 2008; 167: 492-9.
<https://academic.oup.com/aje/article/167/4/492/233064/Immortal-Time-Bias-in-Pharmacoepidemiology>

Suissa S. Immeasurable time bias in observational studies of drug effects on mortality. *Am J Epidemiol* 2008; 168(3): 329-35.
<https://www.ncbi.nlm.nih.gov/pubmed/18515793>

Suissa S. The case-time-control design. *Epidemiology* 1995; 6(3): 248-53.
<https://www.ncbi.nlm.nih.gov/pubmed/7619931>

Suissa S, Azoulay L. Metformin and the Risk of Cancer. Time-related biases in observational studies. *Diabetes Care* 2012; 35(12): 2665-73.
<https://www.ncbi.nlm.nih.gov/pubmed/23173135>

Suissa S, Dell'aniello S, Vahey S, Renoux C. Time-window Bias in Case-control Studies. Statins and Lung Cancer. *Epidemiology* 2011; 22 (2): 228-31.
<https://www.ncbi.nlm.nih.gov/pubmed/21228697>

Swanson SA, Hernán MA. Commentary: how to report instrumental variable analyses (suggestions welcome). *Epidemiology*. 2013; 24(3): 370-4.
<https://www.ncbi.nlm.nih.gov/pubmed/23549180>

Swanson SA, Robins JM, Miller M, Hernán MA. Selecting on treatment: a pervasive form of bias in instrumental variable analyses. *Am J Epidemiol*. 2015; 181(3): 191-7.
<https://academic.oup.com/aje/article/181/3/191/2739229/Selecting-on-Treatment-A-Pervasive-Form-of-Bias-in>

Tadrous M, Gagne JJ, Stürmer T, Cadarette SM. Disease risk score as a confounder summary method: systematic review and recommendations. *Pharmacoepidemiol Drug Saf* 2013; 22(2): 122-29.
<https://www.ncbi.nlm.nih.gov/pubmed/23172692>

Tannen RL, Weiner MG, Xie D. Replicated studies of two randomized trials of angiotensin-converting enzyme inhibitors: further empiric validation of the 'prior event rate ratio' to adjust for unmeasured confounding by indication. *Pharmacoepidemiol Drug Saf.* 2008;17:671-685.
<http://onlinelibrary.wiley.com/doi/10.1002/pds.1584/abstract>

Tatonetti NP, Ye PP, Daneshjou R, Altman RB. Data-driven prediction of drug effects and interactions. *Sci. Transl. Med.* 2012 4, 125ra31.
<http://stm.sciencemag.org/content/4/125/125ra31>

Théophile H, Laporte JR, Moore N, Martin KL, Bégaud B. The case-population study design: an analysis of its application in pharmacovigilance. *Drug Saf* 2011; 34(10):861-8.
<https://www.ncbi.nlm.nih.gov/pubmed/21879780>

Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, Tunis S, Bergel E, Harvey I, Magid DJ, Chalkidou K. Pragmatic explanatory continuum summary (PRECIS): a tool to help trial designers. *CMAJ* 2009; 180: E45-57.
<http://www.cmaj.ca/content/180/10/E47.full.pdf+html>

Toh S, García Rodríguez LA, Hernán MA. Confounding adjustment via a semi-automated high-dimensional propensity score algorithm: an application to electronic medical records. *Pharmacoepidemiol Drug Saf* 2012;20:849-57.
<https://www.ncbi.nlm.nih.gov/pubmed/21717528>

Uddin J, Groenwold RHH, de Boer A, Afonso ASM, Primates P, Becker C, Belitser SV, Hoes AW, Roes KCB, Klungel OH. Evaluating different physician's prescribing preference based instrumental variables in two primary care databases: a study of inhaled long-acting beta2-agonist use and the risk of myocardial infarction. *Pharmacoepidemiol Drug Saf.* 2016; 25 Suppl 1:132-41.
<http://onlinelibrary.wiley.com/doi/10.1002/pds.3860/abstract>

Uddin MJ, Groenwold RH, de Boer A, Belitser SV, Roes KC, Hoes AW, Klungel OH. Performance of instrumental variable methods in cohort and nested case-control studies: a simulation study. *Pharmacoepidemiol Drug Saf* 2014; 2014; 23(2):165-77.
<https://www.ncbi.nlm.nih.gov/pubmed/24306965>

Uddin MJ, Groenwold RH, van Staa TP, de Boer A, Belitser SV, Hoes AW, Roes KCB, Klungel OH. Performance of prior event rate ratio adjustment method in pharmacoepidemiology: a simulation study. *Pharmacoepidemiol Drug Saf.* 2015; 24:468-477.
<http://onlinelibrary.wiley.com/doi/10.1002/pds.3724/abstract>

Van Holle L, Bauchau V. Use of logistic regression to combine two causality criteria for signal detection in vaccine spontaneous report data, *Drug Saf* 2014; 37(12):1047-57.
<https://www.ncbi.nlm.nih.gov/pubmed/25395263>

van Staa TP, Abenhaim L, Leufkens H. A study of the effects of exposure misclassification due to the time-window design in pharmacoepidemiologic studies. *Clin Epidemiol* 1994; 47(2):183-89.
<https://www.ncbi.nlm.nih.gov/pubmed/8113827>

van Staa TP, Dyson L, McCann G, Padmanabhan S, Belatri R, Goldacre B, Cassell J, Pirmohamed M, Torgerson D, Ronaldson S, Adamson J, Taweel A, Delaney B, Mahmood S, Baracaia S, Round T, Fox R, Hunter T, Gulliford M, Smeeth L. The opportunities and challenges of pragmatic point-of-care randomised trials using routinely collected electronic records: evaluations of two exemplar trials. *Health Technol Assess.* 2014; 18(43):1-146.
<https://www.ncbi.nlm.nih.gov/pubmed/25011568>

van Staa TP, Goldacre B, Gulliford M, Cassell J, Pirmohamed M, Taweel A, Delaney B, Smeeth L. Pragmatic randomised trials using routine electronic health records: putting them to the test. *BMJ* 2012; 344:e55.
<http://www.bmj.com/content/344/bmj.e55>

Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *Epidemiology* 2007; 18:805-35.
<https://www.ncbi.nlm.nih.gov/pubmed/18049195>

VanderWeele TJ. On the distinction between interaction and effect modification. *Epidemiology.* 2009; 20:863-71.
<https://www.ncbi.nlm.nih.gov/pubmed/19806059>

Wang S, Linkletter C, Maclure M, Dore D, Mor V, Buka S, Wellenius GA. Future cases as present controls to adjust for exposure trend bias in case-only studies. *Epidemiology* 2011; 22:568-74.
<https://www.ncbi.nlm.nih.gov/pubmed/21577117>

Weldeselassie YG, Whitaker HJ, Farrington CP. Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice. *Epidemiol Infect* 2011; 139(12):1805-17.
<https://www.ncbi.nlm.nih.gov/pubmed/21849099>

Wettermark B, Di Martino M, Elsevier M. *Drug Utilization Research - Methods and Applications*. 1st Edition. John Wiley & Sons; 2016.

Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled case series method. *Stat Med* 2006; 25(10):1768-97.
<https://www.ncbi.nlm.nih.gov/pubmed/16220518>

Wisniewski AF, Bate A, Bousquet C, Brueckner A, Candore G, Juhlin K, Macia-Martinez MA, Manlik K, Quarcoo N, Seabroke S, Slattery J, Southworth H, Thakrar B, Tregunno P, Van Holle L, Kayser M, Norén GN. Good Signal Detection Practices: Evidence from IMI PROTECT. *Drug Saf*. 2016; 39:469-90.
<https://www.ncbi.nlm.nih.gov/pubmed/26951233>

Witteman JC, D'Agostino RB, Stijnen T, Kannel WB, Cobb JC, de Ridder MA, Hofman A, Robins JM. G-estimation of Causal Effects: Isolated Systolic Hypertension and Cardiovascular Death in the Framingham Heart Study. *Am J Epidemiol* 1998; 148(4):390-401.
<https://www.ncbi.nlm.nih.gov/pubmed/9717884>

Xu S, Zhang L, Nelson JC, Zeng C, Mullooly J, McClure D, Glanz J. Identifying optimal risk windows for self-controlled case series studies of vaccine safety. *Stat Med* 2011; 30(7):742-52.
<https://www.ncbi.nlm.nih.gov/pubmed/21394750>

Zhou Z, Rahme E, Abrahamowicz M, Pilote L. Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. *Am J Epidemiol* 2005; 162:1016-23.
<https://www.ncbi.nlm.nih.gov/pubmed?term=PMID:%20%20%20%20%2016192344>

Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Gent M, Oxman AD, Moher D, for the CONSORT and Pragmatic Trials in Healthcare (Practihc) groups. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. *BMJ* 2008; 337 (a2390): 1-8.
<http://www.bmj.com/content/337/bmj.a2390>

References – Chapter 6

Gail MH, Benichou J, Editors. *Encyclopedia of Epidemiologic Methods*. Wiley, 2000.

ICH E9 'Statistical Principles for Clinical Trials'
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002928.pdf

Jones MP. Indicator and Stratification Methods for Missing Explanatory Variables in Multiple Linear Regression. *J Am Stat Assoc* 1996; 91(433):222–230.
http://www.jstor.org/stable/2291399?seq=1#page_scan_tab_contents

Lee KJ, Carlin JB. Recovery of information from multiple imputation: a simulation study. *Emerg Themes Epidemiol* 2012; 9(1): 3.
<http://www.ncbi.nlm.nih.gov/pubmed/22695083>

Moons K, Donders R, Stijnen T, Harrell F. Using the outcome for imputation of missing predictor values was preferred. *J Clin Epi* 2006; 59(10):1092-101.
<http://www.ncbi.nlm.nih.gov/pubmed/16980150>

Rosenbaum PR. *Design of Observational Studies*. Springer, 2010.

Rothman K, Greenland S, Lash T. *Modern Epidemiology*. 3rd Edition, Lippincott Williams & Wilkins, 2008.

Rubin DB. *Multiple Imputation for Nonresponse in Surveys*. Wiley, 1987.

Welch CA, Petersen I, Jonathan W, Bartlett, White IR, Marston L, Morris RW, Nazareth I, Walters K, Carpenter J. Evaluation of two-fold fully conditional specification multiple imputation for longitudinal electronic health record data. *Stat Med*. 2014; 33:3725-37.
<http://onlinelibrary.wiley.com/doi/10.1002/sim.6184/abstract>

References – Chapter 7

AHRQ. Registries for Evaluating Patient Outcomes: A User's Guide: 3rd Edition.
<http://www.effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productID=1897>

Blomgren KJ, Sundström A, Steineck G, Wiholm BE. Interviewer variability - quality aspects in a case-control study. *Eur J Epidemiol*. 2006; 21(4):267-77.
<https://www.ncbi.nlm.nih.gov/pubmed/16685577>

- Commission Implementing Regulation (EU) No. 520/2012 of 19 June 2012.
<http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2012:159:0005:0025:EN:PDF>
- Elmore; Training, Quality Assurance, and Assessment of Medical Record Abstraction in a Multisite Study. *Am J Epidemiol* 2003; 157 (6): 546-551
<https://academic.oup.com/aje/article/157/6/546/74983/Training-Quality-Assurance-and-Assessment-of>
- European Forum for Good Clinical Practice (EFCGP) Guidelines
<http://www.efgcp.eu/Publications.asp?Type=EFGCP%20publications&L1=13&L2=1>
- FDA's Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Health Care Data Sets
<https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM243537.pdf> [Good Practice in Secondary Data Analysis](#).
- Furu, Establishment of the nationwide Norwegian Prescription Database (NorPD) – new opportunities for research in pharmacoepidemiology in Norway, *Norsk epidemiologi* 2008; 18(2):129-36
<http://www.ntnu.no/ojs/index.php/norepid/article/view/23>
- Genell L, Guidelines for Quality Assurance in Multicenter Trials: A Position Paper, *Controlled Clinical Trials*, Volume 19, Issue 5, October 1998, Pages 477-493,
<http://www.sciencedirect.com/science/article/pii/S0197245698000336>
- German Society for Epidemiology (DGEpi). Good Practice in Secondary Data Analysis Version 2.
http://dgepi.de/fileadmin/pdf/leitlinien/gps-version2-final_ENG.pdf
- Herrett, E., Thomas, S. L., Schoonen, W. M., Smeeth, L. and Hall, A. J. (2010), Validation and validity of diagnoses in the General Practice Research Database: a systematic review. *British Journal of Clinical Pharmacology*, 69
<http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.2009.03537.x/full>
- Hoven JL, Haaijer-Ruskamp FM, Vander Stichele RH; DURQUIM Scientific Committee. Indicators of prescribing quality in drug utilisation research: report of a European meeting (DURQUIM, 13-15 May 2004). *Eur J Clin Pharmacol*. 2005 Jan; 60(11):831-4. Epub 2004 Dec 9
<https://www.ncbi.nlm.nih.gov/pubmed/15592823>
- ICH Guideline for Good Clinical Practice E6(R1)
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf
- Imperial College Academic Health Science Centre (AHSC)'s Quality Control and Quality Assurance SOP
https://workspace.imperial.ac.uk/clinicalresearchgovernanceoffice/Public/JRCO_SOP_025_QCOA%20Final%202012.pdf
- International Standards Organization, ISO 9000 Quality management principles
<http://www.iso.org/iso/pub100080.pdf>
- International Standards Organization, ISO 9000
<http://www.iso.org/iso/home.html>, http://www.iso.org/iso/iso_9000_selection_and_use-2009.pdf
- ISPE Guidelines for Good Pharmacoepidemiology Practices
http://www.pharmacoepi.org/resources/guidelines_08027.cfm
- Lindquist M. Data Quality management in pharmacovigilance, *Drug Safety* 2004; 27 (12): 857-870.
http://www.pvtoolkit.net/toolkit/readers/data_quality_management_in_pv.pdf
- Lisa M. Reisch, Jessica Scura Fosse, Kevin Beverly, Onchee Yu, William E. Barlow, Emily L. Harris, Sharon Rolnick, Mary B. Barton, Ann M. Geiger, Lisa J. Herrinton, Sarah M. Greene, Suzanne W. Fletcher, Joann G.
- McGraw M.J. Principles of Good Clinical Practice Pharmaceutical Press, London, 2010
- Medical Quality Management: Theory and Practice. American College of Medical Quality, Prathibha Varkey. Jones and Bartlett Publishers International, 2010. ISBN-13: 9780763760342
<http://www.jblearning.com/catalog/9780763760342/>
- Reisch LM, Fosse JS, Beverly K, Yu O, Barlow WE, Harris E L, Rolnick S, Barton MB, Geiger AM, Herrinton LJ, Greene SM, Fletcher SW, Elmore JG. Training, Quality Assurance, and Assessment of Medical Record Abstraction in a Multisite Study. *Am J Epidemiol* 2003; 157:546-51.
<http://aje.oxfordjournals.org/content/157/6/546>
- Sprenger K, Nickerson D, Meeker-O'Connell D, Morrison BW. Quality by Design in Clinical Trials: A Collaborative Pilot With FDA. *Therapeutic Innovation & Regulatory Science* 2013; 47:161-66.
<http://dij.sagepub.com/content/early/2012/10/25/0092861512458909.abstract>

Theobald K, Capan M, Herbold M, Schinzel S, Hundt F. Quality assurance in non-interventional studies. GMS German Medical Science. 2009;7:Doc29. doi: 10.3205/000088.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778825/>

Wang V.C.X Encyclopedia of Strategic Leadership and Management- Quantitative Data Analysis for Quality Control in Strategic Management, Wiley 2017

Whitney CW, Lind BK, Wahl PW. Quality assurance and quality control in longitudinal studies. Epidemiol Rev. 1998;20(1):71-80
<https://www.ncbi.nlm.nih.gov/pubmed/9762510>

References – Chapter 8

Benchimol EI, Smeeth L, Guttman A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM; RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLoS Med. 2015; 12(10)
<http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0125620>

Declaration of Helsinki
<https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/>

EU-PAS register
<http://www.encepp.eu/encepp/studiesDatabase.jsp>

Enhancing the Quality and Transparency of Health Research (EQUATOR)- Library for health research reporting
<http://www.equator-network.org/>

Guideline on good pharmacovigilance practices (GVP) Module VI – Management and reporting of adverse reactions to medicinal products.
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp&mid=WC0b01ac058058f32c

ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.
<http://www.icmje.org/recommendations/>

ISPE Guidelines for Good Pharmacoepidemiology Practices, section V
http://www.pharmacoepi.org/resources/guidelines_08027.cfm

FDA's Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Health Care Data Sets
<https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM243537.pdf>

Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF, for the QUORUM Group. Improving the quality of reports of meta-analyses of randomised controlled trials: the Quorum statement. Lancet 1999;354(9193): 1896-900.
<http://www.ncbi.nlm.nih.gov/pubmed/10584742>

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339:b2535.
<http://www.bmj.com/content/339/bmj.b2535?view=long&pmid=19622551>

PRISMA statement
<http://www.prisma-statement.org/>

Schulz KF, Altman DG, Moher D, for the CONSORT Group. Consort 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials. BMJ 2010;340:c332.
<http://www.bmj.com/content/340/bmj.c332>

Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010; 40(1): 35-53.
<http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2362.2009.02234.x/full>

STROBE Statement
<http://www.strobe-statement.org/index.php?id=strobe-home>

Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson D, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB, for the MOOSE Group. Meta-analysis of Observational Studies in Epidemiology. JAMA 2000;283(15):2008-12.
<http://jama.jamanetwork.com/article.aspx?articleid=192614>

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008;61(4):344-9.
<http://strobe-statement.org/index.php?id=strobe-publications>

Kelly WN, Arellano FM, Barnes J, Bergman U, Edwards IR, Fernandez AM, Freedman SB, Goldsmith DI, Huang K, Jones JK, McLeay R, Moore N, Stather RH, Trenque T, Troutman WG, van Puijenbroek E, Williams F, Wise RP; International Society of Pharmacoepidemiology. Guidelines for Submitting Adverse Event Reports for Publication. *Pharmacoepidemiol Drug Saf* 2007; 16(5): 581–7
<http://www.ncbi.nlm.nih.gov/pubmed/17471601>

References – Chapter 9

Agency for Healthcare Research and Quality (AHRQ).
<http://www.ahrq.gov/>

AHRQ. Registries for Evaluating Patient Outcomes: A User's Guide: 3rd Edition.
<http://www.effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productID=1897>

CIOMS. International Ethical Guidelines for Biomedical Research Involving Human Subjects.
http://www.cioms.ch/publications/layout_guide2002.pdf

CIOMS. International Ethical Guidelines for Epidemiological Studies
http://www.cioms.ch/index.php/publications/available-publications/540/view_bl/65/bioethics-and-health-policy-guidelines-and-other-normative-documents/47/international-ethical-guidelines-for-epidemiological-studies?tab=getmybooksTab&is_show_data=1

Commission Implementing Regulation (EU) No. 520/2012 of 19 June 2012.
<http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2012:159:0005:0025:EN:PDF>

Declaration of Helsinki
<https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/>

Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001
http://ec.europa.eu/health/files/eudralex/vol-1/dir_2001_20/dir_2001_20_en.pdf

Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001
<http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:2001L0083:20070126:en:PDF>

Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995
http://ec.europa.eu/justice/policies/privacy/docs/95-46-ce/dir1995-46_part1_en.pdf

Directive 2005/28/EC Guidelines for Good Clinical Practice
<http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2005:091:0013:0019:en:PDF>

ENCePP code of conduct
http://www.encepp.eu/code_of_conduct/index.shtml

EU-PAS register
<http://www.encepp.eu/encepp/studiesDatabase.jsp>

Guideline on good pharmacovigilance practices (GVP) Module VI – Management and reporting of adverse reactions to medicinal products.
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/09/WC500172402.pdf

ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.
<http://www.icmje.org/recommendations/>

IEA Good Epidemiological Practice Guideline (GEP)
<http://ieaweb.org/good-epidemiological-practice-gep/>

International Committee of Medical Journal Editors (ICMJE)
<http://www.icmje.org/>

International Epidemiological Association (IEA)
<http://www.ieaweb.org/>

International Society for Pharmacoepidemiology (ISPE)
<http://www.pharmacoepi.org/>

ISPE Guidelines for Good Pharmacoepidemiology Practices
http://www.pharmacoepi.org/resources/guidelines_08027.cfm

ISPE Guidelines on Data Privacy, Medical Record Confidentiality, and Research in the Interest of Public Health.
<http://www.pharmacoepi.org/resources/privacy.cfm>

Kurz X, Bauchau V, Mahy P, Glismann S, van der Aa LM, Simondon F; ADVANCE consortium. The ADVANCE Code of Conduct for collaborative vaccine studies. *Vaccine*. 2017 Apr 4; 35(15):1844-1855
<https://www.ncbi.nlm.nih.gov/pubmed/28285984>

Regulation (EC) No. 45/2001 of the European Parliament and of the Council of 18 December 2000.
<http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2001:008:0001:0022:EN:PDF>

Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC.
<http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32014R0536&rid=1>

Regulation (EU) No. 1235/2010 of the European Parliament and of the Council of 15 December 2010.
<http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:348:0001:0016:EN:PDF>

References – Chapter 10.1

Agency for Healthcare Research and Quality (AHRQ).
<http://www.ahrq.gov/>

AHRQ. Developing a Protocol for Observational Comparative Effectiveness Research: A User's Guide.
<http://www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=1166>

AHRQ. Methods Guide for Effectiveness and Comparative Effectiveness Reviews.
<http://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?productid=318&pageaction=displayproduct>

AHRQ. Summary Variables in Observational Research: Propensity Scores and Disease Risk Scores. Effective Health Care Program Research Report No. 33. May 2012.
http://www.effectivehealthcare.ahrq.gov/ehc/products/441/1084/Decide33_SummaryVariables_FinalReport_20120515.pdf

AHRQ. The Incident User Design in Comparative Effectiveness Research. Effective Health Care Program Research Report No. 33. May 2012.
http://www.effectivehealthcare.ahrq.gov/ehc/products/442/1086/Decide32_IncidentUserDesign_FinalReport_20120515.pdf

AHRQ. What Is Comparative Effectiveness Research.
<http://effectivehealthcare.ahrq.gov/index.cfm/what-is-comparative-effectiveness-research1/>

Avorn J. In defense of Pharmacoepidemiology-Embracing the Yin and Yang of Drug Research. *N Engl J Med* 2007; 357(22):2219-21.
<http://www.nejm.org/doi/pdf/10.1056/NEJMp0706892>

Berger ML, Mamdani M, Atkins D, Johnson ML. The Good research practices for comparative effectiveness research: defining, reporting and interpreting non-randomised studies of treatment effects using secondary data sources: ISPOR good research practices for retrospective database analysis task force report - Part I. *Value Health* 2009; 12: 1044-52.
<http://www.ispor.org/TaskForces/documents/RDPartI.pdf>

Black N. Why we need observational studies to evaluate effectiveness of health care. *BMJ* 1996; 312(7040): 1215-18.
<http://www.ncbi.nlm.nih.gov/pubmed/8634569>

COMET - Core Outcome Measures in Effectiveness Trials.
<http://www.comet-initiative.org/>

Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. *N Engl J Med* 2000; 342(25):1887-92.
<http://www.nejm.org/doi/full/10.1056/NEJM200006223422507#t=article>

Cox E, Martin BC, Van Staa T, Garbe E, Siebert U, Johnson ML. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of non-randomised studies of treatment effects using secondary data sources: The ISPOR good research practices for retrospective database analysis task force-Part II. *Value Health* 2009; 12: 1053-61.
<http://www.ispor.org/TaskForces/documents/RDPartII.pdf>

Crystal S, Gaboda D, Lucas J, Gerhard T, Chakravarty S. Assessing medication exposures and outcomes in the frail elderly: assessing research challenges in nursing home pharmacotherapy. *Med Care*. 2010 Jun; 48(6 Suppl):S23-31.
<http://www.ncbi.nlm.nih.gov/pubmed/20473191>

DARTNet Institute
<http://www.dartnet.info>

EUnetHTA. Methodological Guidelines for Rapid Relative Effectiveness Assessment of Pharmaceuticals.
<http://www.eunetha.eu/news/final-version-hta-core-model-and-methodological-guidelines-rapid-rea-pharmaceuticals-now-availa>

Gorst SL, Gargon E, Clarke M, Blazeby JM, Altman DG, Williamson PR. Choosing Important Health Outcomes for Comparative Effectiveness Research: An Updated Review and User Survey. PLoS One. 2016 ;11(1):e0146444.
<http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0146444>

GRACE Principles
<http://www.graceprinciples.org/>

GRADE working group. 6-part 2008 BMJ series.
<http://www.gradeworkinggroup.org/publications/index.htm#BMJ2008>

GRADE working group. Journal of Clinical Epidemiology series of articles.
<http://www.jclinepi.com/content/jce-GRADE-Series>

Grading of Recommendations Assessment, Development, and Evaluation (GRADE) working group.
<http://www.gradeworkinggroup.org/index.htm>

Harker J, Kleijnen J. What is a rapid review? A methodological exploration of rapid reviews in Health Technology Assessments. Int J Evid Based Healthc 2012;10(4):397-410.
<http://www.ncbi.nlm.nih.gov/pubmed/23173665>

Hernán MA, Robins JM. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. Am J Epidemiol. 2016 Apr 15;183(8):758-64.
<http://www.ncbi.nlm.nih.gov/pubmed/26994063>

International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
<http://www.ispor.org/>

Johnson ES, Bartman BA, Briesacher BA, Fleming NS, Gerhard T, Kornegay CJ, Nourjah P, Sauer B, Schumock GT, Sedrakyan A, Stürmer T, West SL, Schneeweiss S. The incident user design in comparative effectiveness research. Pharmacoepidemiol Drug Saf. 2013 Jan;22(1):1-6.
<http://www.ncbi.nlm.nih.gov/pubmed/23023988>

Johnson ML, Crown W, Martin BC, Dormuth CR, Siebert U. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from non-randomised studies of treatment effects using secondary data sources: The ISPOR good research practices for retrospective database analysis task force report—Part III. Value Health 2009;12:1062-73.
<http://www.ispor.org/TaskForces/documents/RDPartIII.pdf>

Klungle OH, Martens EP, Psaty BM, Grobbee DE, Sullivan SD, Stricker BH, Leufkens HG, de Boer A. Methods to assess intended effects of drug treatment in observational studies are reviewed. J Clin Epidemiol 2004;57(12):1223-31.
<http://www.ncbi.nlm.nih.gov/pubmed/15617947>

Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ 2015; 350: h2147.
<http://www.bmj.com/content/350/bmj.h2147>

Patient-Centered Outcome Research Institute (PCORI)
<http://www.pcori.org/>

PCORI. Patient Centered Outcomes Research Institute. Draft Methodological Report.
<http://www.pcori.org/assets/PCORI-Methodology-Standards.pdf>

Ray WA. Evaluating medication effects outside of clinical trials: new-user designs Am J Epidemiol 2003;158 (9):915–20.
<http://aje.oxfordjournals.org/content/158/9/915.long>

Real World Evidence Navigator Website
<https://rwe-navigator.eu/>

Sauer BC, Brookhart A, Roy J, Vanderweele T. A Review of Covariate Selection for Nonexperimental Comparative Effectiveness Research. Pharmacoepidemiol Drug Saf 2013 Nov; 22(11): 1139–1145.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190055/>

Schneeweiss S, Avorn J. A review of uses of healthcare utilisation databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005;58:323-37.
<http://www.ncbi.nlm.nih.gov/pubmed/15862718>

Schneeweiss S. Developments in post-marketing comparative effectiveness research (Clin Pharmacol Ther 2007; 82(2): 143-56).

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2905665/>

Selby, Joseph V., Laura Forsythe, and Harold C. Sox. "Stakeholder-driven comparative effectiveness research: an update from PCORI." *Jama* 314.21 (2015): 2235-2236.

<http://jamanetwork.com/journals/jama/fullarticle/2471797?guestAccessKey=bd1f9df0-4ea8-4257-ae8a-83afda60fb84>

Schwartz D, Lellouch J. Explanatory and Pragmatic Attitudes in Therapeutic Trials *J. Clin Epidemiol* 2009; 62(5): 499-505.

<http://www.ncbi.nlm.nih.gov/pubmed/19348976>

Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H and Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. *Epidemiology*. 2009 July ; 20(4): 512–522.

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3077219/pdf/nihms282669.pdf>

Sox HC, Goodman SN. The methods of comparative effectiveness research. *Annu Rev Public Health* 2012; 33:425-45.

<http://www.ncbi.nlm.nih.gov/pubmed/22224891>

Tadrous M, Gagne JJ, Sturmer T, Cadarette SM. Disease Risk Score (DRS) as a Confounder Summary Method; Systematic Review and Recommendations. *Pharmacoepidemiol Drug Saf* 2013; 22: 122–129.

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691557/>

Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, Tunis S, Bergel E, Harvey I, Magid DJ, Chalkidou K. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. *CMAJ* 2009; 180 (10):E47-57.

<http://www.cmaj.ca/content/180/10/E47.full>

Toh S, Gagne JJ, Rassen JA, Fireman BH, Kulldorff M, Brown JS. Confounding adjustment in comparative effectiveness research conducted within distributed research networks. *Med Care*. 2013 Aug; 51(8 Suppl 3):S4-10.

<http://www.ncbi.nlm.nih.gov/pubmed/23752258>

US National Library of Medicine

<http://www.nlm.nih.gov/>

Valuck RJ, Anderson HO, Libby AM, Brandt E, Bryan C, Allen RR, Staton EW, West DR and Pace WD. Enhancing electronic health record measurement of depression severity and suicide ideation: a Distributed Ambulatory Research in Therapeutics Network (DARTNet) study. *J Am Board Fam Med* 2012; 25(5):582-93.

<http://www.ncbi.nlm.nih.gov/pubmed/22956694>

van Staa T, Goldacre B, Gulliford M, Cassell J, Pirmohamed M, Taweel A, Delaney B, Smeeth L. Pragmatic randomised trials using routine electronic health records: putting them to the test *BMJ* 2012; 344: e55.

<http://www.bmj.com/content/344/bmj.e55>

Vandenbroucke P. When are observational studies as credible as randomised trials. *Lancet* 2004; 363(9422):1728-31.

[http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736\(04\)16261-2.pdf](http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(04)16261-2.pdf)

Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D, for the CONSORT and Pragmatic Trials in Healthcare (Practihc) groups. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. *BMJ* 2008; 337 (a2390) :1-8.

<http://www.ncbi.nlm.nih.gov/pubmed/19001484>

References – Chapter 10.2

Andrews N, Waight PA, Borow R, Ladhani S, George RC, Slack MPE, Miller L. Using the Indirect Cohort Design to Estimate the Effectiveness of the Seven Valent Pneumococcal Conjugate Vaccine in England and Wales. *PLoS ONE* 6(12): e28435. doi: 10.1371/journal.pone.0028435.

<http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0028435>

Andrews N. Epidemiological designs for vaccine safety assessment: methods and pitfalls. *Biologicals* 2012; 40(5): 389-92.

<http://www.ncbi.nlm.nih.gov/pubmed/21985898>

Banks D, Woo EJ, Burwen DR, Perucci P, Braun MM, Ball R. Comparing data mining methods on the VAERS database. *Pharmacoepidemiol Drug Saf* 2005; 14(9):601-9.

<http://www.ncbi.nlm.nih.gov/pubmed/15954077>

Beck CR, McKenzie BC, Hashim AB, Harris RC; University of Nottingham. Influenza and the ImmunoCompromised (UNIIC) Study Group, Nguyen-Van-Tam JS Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. *J Infect Dis* 2012; 206(8):1250-9.

<http://www.ncbi.nlm.nih.gov/pubmed/22904335>

Black S, Eskola J, Siegrist CA, Halsey N, Macdonald N, Law B, Miller E, Andrews N, Stowe J, Salmon D, Vannice K, Izurieta HS, Akhtar A, Gold M, Oselka G, Zuber P, Pfeifer D, Vellozzi C. Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. *Lancet* 2009; 374(9707):2115-22.

<http://www.ncbi.nlm.nih.gov/pubmed/19880172>

Brighton Collaboration

<https://brightoncollaboration.org/public>

Brighton Collaboration. Resources to facilitate and harmonise collection, analysis and presentation of vaccine safety data.

<https://brightoncollaboration.org/public/resources.html>

Broome CV, Facklam RR, Fraser DW. Pneumococcal Disease after Pneumococcal Vaccination — An Alternative Method to Estimate the Efficacy of Pneumococcal Vaccine. *N Engl J Med* 1980; 303: 549-552.

<http://www.ncbi.nlm.nih.gov/pubmed/6995835>

Brown JS, Kulldorff M, Chan KA, Davis RL, Graham D, Pettus PT, Andrade SE, Raebel MA, Herrinton L, Roblin D, Boudreau D, Smith D, Gurwitz JH, Gunter MJ, Platt R. Early detection of adverse drug events within population-based health networks: application of sequential methods. *Pharmacoepidemiol Drug Saf* 2007; 16(12):1275-1284.

<http://www.ncbi.nlm.nih.gov/pubmed/17955500>

Carvajal A, Ortega PG, Sáinz M, Velasco V, Salado I, Arias LH, Eiros JM, Rubio AP, Castrodeza J. Adverse events associated with pandemic influenza vaccines: comparison of the results of a follow-up study with those coming from spontaneous reporting. *Vaccine* 2011 Jan 10; 29(3):519-22. doi: 10.1016/j.vaccine.2010.10.067. Epub 2010 Nov 26.

<http://www.ncbi.nlm.nih.gov/pubmed/21112311>

Castilla J, Beristain X, Martínez-Artola V, Navascués A, García Cenoz M, Alvarez N, Polo I, Mazón A, Gil-Setas A, Barricarte A. Effectiveness of rotavirus vaccines in preventing cases and hospitalizations due to rotavirus gastroenteritis in Navarre, Spain. *Vaccine* 2012; 30(3):539-43.

<http://www.ncbi.nlm.nih.gov/pubmed/22122860>

Charlton R, de Vries C, prepared for the European Medicines Agency, Consultancy EMA/2010/29/CN. Systematic overview of data sources for drug safety in pregnancy research.

http://www.encepp.eu/structure/documents/Data_sources_for_medicines_in_pregnancy_research.pdf

CIOMS/WHO Working Group on Vaccine Pharmacovigilance. Definition and Application of Terms for Vaccine Pharmacovigilance. Council for International Organizations of Medical Sciences (CIOMS), Geneva 2012.

http://www.who.int/vaccine_safety/initiative/tools/CIOMS_report_WG_vaccine.pdf

De Bie S, Verhamme KMC, Straus SMJM, Stricker BCH and Sturkenboom MCJM, on behalf of the TEDDY European Network of Excellence. Vaccine-Based Subgroup Analysis in VigiBase: Effect on Sensitivity in Paediatric Signal Detection. *Drug Saf* 2012; 35(4)335-346.

<http://www.ncbi.nlm.nih.gov/pubmed/22435344>

De Serres G, Pilishvili T, Link-Gelles R, Reingold A, Gershman K, Petit S, Farley MM, Harrison LH, Lynfield R, Bennett NM, Baumbach J, Thomas A, Schaffner W, Beall B, Whitney C, Moore M. Use of surveillance data to estimate the effectiveness of the 7-valent conjugate pneumococcal vaccine in children less than 5 years of age over a 9 year period. *Vaccine* 2012; 30(27):4067-72.

http://www.ncbi.nlm.nih.gov/pubmed?cmd=Retrieve&list_uids=22525797&dopt=Abstract

De Vito C, Manzoli L, Marzuillo C, Anastasi D, Boccia A, Villari P. A systematic review evaluating the potential for bias and the methodological quality of meta-analyses in vaccinology. *Vaccine* 2007; 25(52):8794-806.

<http://www.ncbi.nlm.nih.gov/pubmed/18035456>

Dennis J, Hawken S, Krewski D, Birkett N, Gheorghe M, Frei J, McKeown-Eyssen G, Little J. Bias in the case-only design applied to studies of gene-environment and gene-gene interaction: a systematic review and meta-analysis. *Int J Epidemiol* 2011; 40(5):1329-41.

<http://www.ncbi.nlm.nih.gov/pubmed/21729879>

Dudareva-Vizule S, Koch J, An der Heiden M, Oberle D, Keller-Stanislawski B, Wichmann O. Impact of rotavirus vaccination in regions with low and moderate vaccine uptake in Germany. *Hum Vaccin Immunother* 2012; 8(10):1407-15.

<http://www.ncbi.nlm.nih.gov/pubmed/22960495>

ECDC Impact of rotavirus vaccination - Generic Study Protocol.

<http://www.ecdc.europa.eu/en/publications/Publications/Rotavirus-impact-vaccination-April-2013.pdf>

Effectiveness of rotavirus vaccination – Generic study protocol for retrospective cohort studies based on computerised databases

<http://ecdc.europa.eu/en/publications/Publications/rotavirus-vaccination-cohort-study-april2013.pdf>

- Escolano S, Farrington P, Hill C, Tubert-Bitter P. Intussusception after Rotavirus Vaccination — Spontaneous Reports (Correspondence). *N Engl J Med* 2011; 365:2139.
<http://www.nejm.org/doi/full/10.1056/NEJMc1107771>
- Escolano S, Hill C, Tubert-Bitter P. A new self-controlled case series method for analyzing spontaneous reports of adverse events after vaccination. *Am J Epidemiol* 2013; 178(9): 1496-504.
<http://www.ncbi.nlm.nih.gov/pubmed/24013203>
- Evans SJW. Stratification for Spontaneous Report Databases. *Drug Saf* 2008; 31(11):1049-52.
<http://www.ncbi.nlm.nih.gov/pubmed/18840024>
- Farrington CP, Firth MJ, Moulton LH, Ravn H, Andersen PK, Evans S; Working Group on Non-specific Effects of Vaccines. Epidemiological studies of the non-specific effects of vaccines: II--methodological issues in the design and analysis of cohort studies. *Trop Med Int Health* 2009 Sep; 14(9):977-85.
<http://www.ncbi.nlm.nih.gov/pubmed/19531116>
- Farrington CP. Control without separate controls: evaluation of vaccine safety using case-only methods. *Vaccine* 2004; 22(15-16):2064-70.
<http://www.ncbi.nlm.nih.gov/pubmed/15121324>
- Fine PE, Williams TN, Aaby P, Källender K, Moulton LH, Flanagan KL, Smith PG, Benn CS; Working Group on Non-specific Effects of Vaccines. Epidemiological studies of the 'non-specific effects' of vaccines: I--data collection in observational studies. *Trop Med Int Health* 2009 Sep; 14(9):969-76.
<http://www.ncbi.nlm.nih.gov/pubmed/19531117>
- Glanz JM, McClure DL, Xu S, Hambidge SJ, Lee M, Kolczak MS, Kleinman K, Mullooly JP, France EK. Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations. *J Clin Epidemiol* 2006 Aug; 59(8):808-18.
<http://www.ncbi.nlm.nih.gov/pubmed/16828674>
- Greene SK, Kullendorff M, Yin R, Yih WK, Lieu TA, Weintraub ES, Lee GM. Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project. *Am J Epidemiol* 2010; 171(2): 177-88.
<http://www.ncbi.nlm.nih.gov/pubmed/19965887>
- Guideline on good pharmacovigilance practices (GVP): Module P.I: Vaccines for prophylaxis against infectious diseases.
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp&mid=WC0b01ac058058f32c#section3
- Halloran ME, Haber M, Longini IM Jr, Struchiner CJ. Direct and indirect effects in vaccine efficacy and effectiveness. *Am J Epidemiol* 1991; 133(4):323-31.
http://www.tc.umn.edu/~alonso/Halloran_AJE_1991.pdf
- Hanquet G, Valenciano M, Simondon F, Moren A. Vaccine effects and impact of vaccination programmes in post-licensure studies. *Vaccine* 2013; 31(48):5634-42.
<http://www.ncbi.nlm.nih.gov/pubmed/23856332>
- Heffernan JM, Keeling MJ. Implications of vaccination and waning immunity. *Proc Biol Sci* 2009; 276(1664):2071-80.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2677258/>
- Heininger U, Holm K, Caplanusi I, Bailey SR; CIOMS Working Group on Vaccine Safety. Guide to active vaccine safety surveillance: Report of CIOMS working group on vaccine safety - executive summary. *Vaccine*. 2017
<https://www.ncbi.nlm.nih.gov/pubmed/?term=heininger+guide+to+active+vaccine+safety>
- Hennessy S, Liu Z, Tsai TF, Strom BL, Wan CM, Liu HL, Wu TX, Yu HJ, Liu QM, Karabatsos N, Bilker WB, Halstead SB. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. *Lancet* 1996; 347(9015):1583-6.
<http://www.ncbi.nlm.nih.gov/pubmed/8667866>
- Hocine MN, Farrington CP, Touzé E, Whitaker HJ, Fourrier A, Moreau T, Tubert-Bitter P. Hepatitis B vaccination and first central nervous system demyelinating events: Reanalysis of a case-control study using the self-controlled case series method. *Vaccine* 2007; 25(31):5938-43.
<http://www.ncbi.nlm.nih.gov/pubmed/17597263>
- Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. *Vaccine* 2013 Apr 19; 31(17):2165-8. doi: 10.1016/j.vaccine.2013.02.053.
<http://www.ncbi.nlm.nih.gov/pubmed/23499601>
- Jefferson T, Rivetti D, Rudin M, Di Pietrantonio C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. *Lancet* 2005; 366(9492):1165-74.
<http://www.ncbi.nlm.nih.gov/pubmed/16198765>
- Klein NP (2011) Vaccine safety in special populations, *Human Vaccines*, 7:2, 269-271, DOI: 10.4161/hv.7.2.13860.
<http://dx.doi.org/10.4161/hv.7.2.13860>

Kurz X, Domergue F, Slattery J, Segec A, Szmigiel A, Hidalgo-Simon A. Safety monitoring of Influenza A/H1N1 pandemic vaccines in EudraVigilance. *Vaccine* 2011; 29(26): 4378-87.
<http://www.ncbi.nlm.nih.gov/pubmed/21501644>

Leino T, Ollgren J, Salo H, Tiihonen P, Kilpi T. First year experience of rotavirus immunisation programme in Finland. *Vaccine* 2012; 31(1): 176-82.
<http://www.ncbi.nlm.nih.gov/pubmed/23122991>

Martín Arias LH, Sanz R, Sáinz M, Treceño C, Carvajal A. Guillain-Barré syndrome and influenza vaccines: A meta-analysis. *Vaccine*. 2015 Jul 17; 33(31): 3773-8.
<https://www.ncbi.nlm.nih.gov/pubmed/25999283>

McClure DL, Glanz JM, Xu S, Hambidge SJ, Mullooly JP, Baggs J. Comparison of epidemiologic methods for active surveillance of vaccine safety. *Vaccine* 2008; 26(26): 3341-3345.
<http://www.ncbi.nlm.nih.gov/pubmed/18462849>

Miller E, Andrews N, Stellitano L, Stowe J, Winstone AM, Shneerson J, Verity C. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. *BMJ* 2013; 346:f794.
<http://www.ncbi.nlm.nih.gov/pubmed/23444425>

Module 4 (Surveillance)

<http://vaccine-safety-training.org/overview-and-outcomes-4.html>

Nelson JC, Cook AJ, Yu O, Dominguez C, Zhao S, Greene SK, Fireman BH, Jacobsen SJ, Weintraub ES, Jackson LA. Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data. *Pharmacoepidemiol Drug Saf* 2012; 21(S1): 62-71.
<http://www.ncbi.nlm.nih.gov/pubmed/22262594>

Polyzos KA, Konstantelias AA, Pitsa CE, Falagas ME. Maternal Influenza Vaccination and Risk for Congenital Malformations: A Systematic Review and Meta-analysis. *Obstet Gynecol*. 2015 Nov; 126(5): 1075-84.
<https://www.ncbi.nlm.nih.gov/pubmed/26444106>

Pritchard JK, Stephens M, Rosenberg NA, Donnelly P. Association mapping in structured populations. *Am J Hum Genet*. 2000. 67(1): 170-171
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1287075/>

Remschmidt C, Rieck T, Bödeker B, Wichmann O. Application of the screening method to monitor influenza vaccine effectiveness among the elderly in Germany. *BMC Infect Dis* 2015; 15: 137.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4371628/>

Salmon DA, Proschan M, Forshee R, Gargiullo P, Bleser W, Burwen DR, Cunningham F, Garman P, Greene SK, Lee GM, Vellozzi C, Yih WK, Gellin B, Lurie N; H1N1 GBS Meta-analysis Working Group. Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. *Lancet* 2013 Apr 27; 381(9876): 1461-8.
<http://www.ncbi.nlm.nih.gov/pubmed/23498095>

Siegrist CA, Lewis EM, Eskola J, Evans SJ, Black SB. Human papilloma virus immunization in adolescents and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. *Pediatr Infect Dis J* 2007; 26(11): 979-84.
<http://www.ncbi.nlm.nih.gov/pubmed/17984802>

Simpson CR, Lone NI, Kavanagh K, Ritchie LD, Robertson C, Sheikh A, McMenamin J. Trivalent inactivated seasonal influenza vaccine effectiveness for the prevention of laboratory-confirmed influenza in a Scottish population 2000 to 2009. *Euro Surveill* 2015 Feb 26; 20(8). pii: 21043.
<http://www.ncbi.nlm.nih.gov/pubmed/25742433>

Tokars JI, Lewis P, DeStefano F, Wise M, Viray M, Morgan O, Gargiullo P, Vellozzi C. The risk of Guillain-Barre Syndrome associated with influenza A (H1N1) 2009 monovalent vaccine and 2009-2010 seasonal influenza vaccines: Results from self-controlled analyses. *Pharmacoepidemiol Drug Safety* 2012; 21(5): 546-52.
<http://www.ncbi.nlm.nih.gov/pubmed/22407672>

Vaccine Safety Basics e-learning course (World Health Organization)
<http://www.vaccine-safety-training.org/home.html>

Vaccine Safety Datalink (VSD)
<http://www.cdc.gov/vaccinesafety/Activities/VSD.html>

Van Ganse E, Letrilliant L, Borne H, Morand F, Robain M, Siegrist CA. Health problems most commonly diagnosed among young female patients during visits to general practitioners and gynecologists in France before the initiation of the human papillomavirus vaccination program. *Pharmacoepidemiol Drug Saf* 2012 Mar; 21(3): 261-8.
<http://www.ncbi.nlm.nih.gov/pubmed/22052698>

Wacholder S, Chen BE, Wilcox A, Macones G, Gonzalez P, Befano B, Hildesheim A, Rodríguez AC, Solomon D, Herrero R, Schiffman M; CVT group. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. *BMJ* 2010; 340:c712.
<http://www.ncbi.nlm.nih.gov/pubmed/20197322>

Woo EJ, Ball R, Burwen DR, Braun MM. Effects of stratification on data mining in the US Vaccine Adverse Event Reporting System (VAERS). *Drug Saf* 2008;31(8):667-74.
<http://www.ncbi.nlm.nih.gov/pubmed/18636785>

Xu R, Lo Y, Chamber C. Assessing the effect of vaccine on spontaneous abortion using time-dependent covariates Cox models. *Pharmacoepidemiol Drug Saf* 2012;21(8):844-850.
<http://www.ncbi.nlm.nih.gov/pubmed/22674821>

Yih WK, Kulldorff M, Fireman BH, Shui IM, Lewis EM, Klein NP, Baggs J, Weintraub ES, Belongia EA, Naleway A, Gee J, Platt R, Lieu TA. Active surveillance for adverse events: the experience of the Vaccine Safety Datalink Project. *Pediatrics* 2011; 127(S1):S54-S64.
<http://www.ncbi.nlm.nih.gov/pubmed/21502252>

References – Chapter 10.3

Amstutz U, Shear NH, Rieder MJ, Hwang S, Fung V, Nakamura H, Connolly MB, Ito S, Carleton BC; CPNDS clinical recommendation group. Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions (*Epilepsia* 2014 Apr;55(4):496-506).
<http://www.ncbi.nlm.nih.gov/pubmed/24597466>

Balding DJ. A tutorial on statistical methods for population association studies. *Nat Rev Genet* 2006;7(10):781-91.
<http://www.ncbi.nlm.nih.gov/pubmed/16983374>

Bozkurt O, Verschuren WM, van Wieren-de Wijer BM, Knol MJ, de Boer A, Grobbee DE, Geerlings MI, Heerdink ER, Klungel OH. Genetic variation in the renin-angiotensin system modifies the beneficial effects of ACE inhibitors on the risk of diabetes mellitus among hypertensives, *Hum Hypertens* 2008;22(11):774-80.
<http://www.ncbi.nlm.nih.gov/pubmed/18563171>

Carleton B, Poole R, Smith M, Leeder J, Ghannadan R, Ross C, Phillips M, Hayden M. Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals, *Pharmacoepidemiol Drug Saf* 2009;18(8):713-21.
<http://www.ncbi.nlm.nih.gov/pubmed/19507171>

Carr DF, O'Meara H, Jorgensen AL, Campbell J, Hobbs M, McCann G, van Staa T, Pirmohamed M. SLC01B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. *Clin Pharmacol Ther* 2013;94(6):695-701.
<http://www.ncbi.nlm.nih.gov/pubmed/23942138>

CPIC: Clinical Pharmacogenetics Implementation Consortium
<https://www.pharmgkb.org/page/cpic>

Dennis J, Hawken S, Krewski D, Birkett N, Gheorghe M, Frei J, McKeown-Eyssen G, Little J. Bias in the case-only design applied to studies of gene-environment and gene-gene interaction: a systematic review and meta-analysis. *Int J Epidemiol* 2011;40(5):1329-41.
<http://www.ncbi.nlm.nih.gov/pubmed/21729879>

Drews J. Drug discovery: a historical perspective. *Science* 2000;287(5460):1960-4.
<http://www.ncbi.nlm.nih.gov/pubmed/10720314>

Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. *Nature* 2004;429(6990):464-8.
<http://www.ncbi.nlm.nih.gov/pubmed/15164072>

Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. *Science* 1999;286(5439):487-91.
<http://www.ncbi.nlm.nih.gov/pubmed/10521338>

Gatto NM, Campbell UB, Rundle AG, Ahsan H. Further development of the case-only design for assessing gene-environment interaction: evaluation of and adjustment for bias. *Int J Epidemiol* 2004;33(5):1014-24.
<http://www.ncbi.nlm.nih.gov/pubmed/15358745>

Grady BJ, Ritchie MD. Statistical Optimization of Pharmacogenomics Association Studies: Key Considerations from Study Design to Analysis. *Curr Pharmacogenomics Person Med* 2011 Mar 1;9(1):41-66.
<http://www.ncbi.nlm.nih.gov/pubmed/21887206>

Jorgensen AL, Williamson PR. Methodological quality of pharmacogenetic studies: issues of concern. *Stat Med* 2008;27(30):6547-69.
<http://www.ncbi.nlm.nih.gov/pubmed/18837075>

Khoury MJ, Flanders WD. Nontraditional epidemiologic approaches in the analysis of gene-environment interaction: case-control studies with no controls! *Am J Epidemiol* 1996;144(3):207-13).
<http://www.ncbi.nlm.nih.gov/pubmed/8686689>

Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N. STrengthening the REporting of Genetic Association studies (STREGA)--an extension of the STROBE statement. *Eur J Clin Invest* 2009;39(4):247-66.
<http://www.ncbi.nlm.nih.gov/pubmed/19297801>

Liu Y, Nyunoya T, Leng S, Belinsky SA, Tesfaigzi Y, Bruse S. Softwares and methods for estimating genetic ancestry in human populations (*Hum Genomics*. 2013; 7: 1).
<http://www.ncbi.nlm.nih.gov/pubmed/23289408>

Madadi P, Amstutz U, Rieder M, Ito S, Fung V, Hwang S, Turgeon J, Michaud V, Koren G, Carleton BC; CPNDS Clinical Recommendations Group. Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy. *J Popul Ther Clin Pharmacol* 2013;20(3):e369-96.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=Madadi+Amstutz>

Molokhia M, McKeigue P. EUDRAGENE: European collaboration to establish a case-control DNA collection for studying the genetic basis of adverse drug reactions 2006;7(4):633-8.
<http://www.ncbi.nlm.nih.gov/pubmed/16753010>

Peters BJ, Rodin AS, de Boer A, Maitland-van der Zee AH. Methodological and statistical issues in pharmacogenomics. *J Pharm Pharmacol* 2010;62(2):161-6.
<http://www.ncbi.nlm.nih.gov/pubmed/20487194>

PharmGKB (The Pharmacogenomics Knowledgebase)
<https://www.pharmgkb.org/>

Pritchard JK, Stephens M, Rosenberg NA, Donnelly P. Association mapping in structured populations. *Am J Hum Genet*. 2000. 67(1): 170-171
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1287075/>

Psaty BM, Smith NL, Heckbert SR, Vos HL, Lemaitre RN, Reiner AP, Siscovick DS, Bis J, Lumley T, Longstreth WT Jr, Rosendaal FR. Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. *JAMA* 2002;287(13):1680-9.
<http://www.ncbi.nlm.nih.gov/pubmed/11926892>

Ross S, Anand SS, Joseph P, Paré G. Promises and challenges of pharmacogenetics: an overview of study design, methodological and statistical issues. *JRSM Cardiovasc Dis* 2012;5;1(1).
<http://www.ncbi.nlm.nih.gov/pubmed/24175062>

Storey JD, Tibshirani R. Statistical significance for genomewide studies. *Proc Natl Acad Sci USA* 2003;100(16):9440-5.
<http://www.ncbi.nlm.nih.gov/pubmed/12883005>

van der Baan FH, Klungel OH, Egberts AC, Leufkens HG, Grobbee DE, Roes KC, Knol MJ. Pharmacogenetics in randomized controlled trials: considerations for trial design. *Pharmacogenomics* 2011;12(10):1485-92.
<http://www.ncbi.nlm.nih.gov/pubmed/22008051>

van der Baan FH, Knol MJ, Klungel OH, Egberts AC, Grobbee DE, Roes KC. Potential of adaptive clinical trial designs in pharmacogenetic research. *Pharmacogenomics* 2012;13(5):571-8.
<http://www.ncbi.nlm.nih.gov/pubmed/22462749>

van Wieren-de Wijer DB¹, Maitland-van der Zee AH, de Boer A, Kroon AA, de Leeuw PW, Schiffers P, Janssen RG, Psaty BM, van Duijn CM, Stricker BH, Klungel OH. Interaction between the Gly460Trp alpha-adducin gene variant and diuretics on the risk of myocardial infarction. *J Hypertens* 2009 Jan;27(1):61-8.
<http://www.ncbi.nlm.nih.gov/pubmed/19145769>

Zhang H, Liu L, Wang X, Gruen JR. Guideline for data analysis of genomewide association studies. *Cancer Genomics Proteomics* 2007;4(1):27-34.
<http://www.ncbi.nlm.nih.gov/pubmed/17726238>